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Abstract 
Mackenzie, A., Studies on the Biosynthetic Pathways of Clavulanic Acid and Cephamycin 
C in Streptomyces clavuligerus. Doctoral dissertation. 
ISSN 1652-6880 ISBN 978-91-576-7318-3 
 
The discovery of penicillin, a β-lactam antibiotic, changed the way humans thought about 
infectious disease. Unfortunately, the widespread use of antibiotics has lead to a 
concomitant increase in bacterial resistance to these drugs. One of the most common 
mechanisms of bacterial resistance to β-lactam antibiotics is mediated through the 
hydrolysis of the β-lactam ring by β-lactamases. In order to combat resistance two strategies 
have been employed: identification of antibiotics resistant to hydrolysis by β-lactamases, 
and the development of β-lactamase inhibitors. This thesis describes studies on 
enzymes/proteins in the biosynthetic pathways of β-lactam antibiotics and β-lactamase 
inhibitors. 
 
DAOCS is a non-heme Fe(II) dioxygenase that catalyses the oxidative ring expansion of the 
penicillins to cephalosporins. The expansion of the five-membered penicillin ring to a six-
membered cephem ring provides increased resistance to β-lactamases. The work described 
here led to the production of crystals with an alternate packing of molecules (belonging to a 
new space group), which did not show twinning, an anomaly hampering previous structural 
work.  
 
Clavulanic acid is a potent inhibitor of class A bacterial β-lactamases. CAD is a short chain 
reductase responsible for the catalysis of the penultimate step in clavulanic acid 
biosynthesis: the NADPH-dependent reduction of the unstable intermediate clavulanate-9-
aldehyde to clavulanic acid. Structures of CAD in complex with the NADPH co-factor, and 
clavulanic acid, are described here, leading to a proposed reaction mechanism, and an 
increased understanding of how the enzyme is able to catalyse a reaction involving such a 
labile intermediate. 
 
Approximately half of the genes in the clavulanic acid biosynthesis gene cluster are open 
reading frames, without a known function. The gene product of Orf15 has been shown to be 
essential for clavulanic acid production. The structure reported here reveals that it shares 
similarity with substrate-binding proteins. The complex of ORF15 with L-arginine, a 
precursor of clavulanic acid, suggests multiple roles for the protein. 
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oxygenase, short chain dehydrogenase, oligopeptide-binding protein, clavulanic acid 
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 Abbreviations 
2ODD     2-oxoglutarate  dependent  dioxygenase 
AAA            L-a-aminoadipic  acid 
A C V        δ(L-a-aminoadipyl)-L-cysteinyl-D-valine 
B L S       β-lactam synthase 
CAD       clavulanic  acid  dehydrogenase 
CAS       clavaminic  acid  synthase 
C E A S       N
2-(2-carboxyethyl)arginine synthase 
DAC-AT     deacetylcephalosporin  acetyl  transferase   
DAOC        deacetoxycephalosporin  C 
DAOCS       deacetoxycephalosporin  C  synthase 
DAOCS/DACS  deacetoxy/deacetylcephalosporin synthase  
IAT        acyl  coenzyme  A:isopenicillin  N  acyltransferase 
IPNS       isopenicillin  N  synthase 
OAT2     ornithine  acetyl  transferase 
MIR         multiple  isomorphous  replacement 
MAD       multiple-wavelength  anomalous  diffraction 
NADPH    nicotinamide  adenine dinucleotide (reduced form) 
NAM       N-acetylmuramic  acid 
NAG       N-acetyl-glucosamine 
NCS       non-crystallographic  symmetry 
ORF          open  reading  frame 
MIR         multiple  isomorphous  replacement 
PAH       proclavaminate  amidinohydrolase 
PBP         penicillin  binding  protein 
PEG         polyethylene  glycol 
r.m.s          root  mean  square 
SAD         single-wavelength  anomalous  diffraction 
SBP         substrate-binding  protein 
SDR       short  chain  dehydrogenase/reductase 
Å          å n g s t r ö m   
Foreword.  Poor Old Noah 
Noah is one of the few distinguished people acknowledged as a prophet in three of 
the world’s religions. With such high accolades we can assume that Noah was a 
wise man. Noah is accredited with the rescue of all animal and bird species, after a 
cataclysmic deluge of rain lasting 40 days and 40 nights (Gen. 7:4 New 
International Version) purportedly flooded the earth for one hundred and fifty days 
(Gen. 7:24). While, there is no specific reference to plant species, one can assume 
that a diligent Noah was also responsible for plant conservation, as he is reported 
to have grown the first vineyard upon returning to terra firma (Gen. 9:20). If this is 
true for plants, then one wonders if Noah was also responsible for the preservation 
of microorganisms, although anaerobic bacteria, and viral species may have 
struggled to justify their apparent journey on the Ark (Gen. 7:15). 
 
Judging from the number of species present on earth today it is easy to see that 
Noah took his job seriously, obviously undergoing great hardship in order to 
collect some of these species. The preservation of bacterial species such as 
Neisseria gonorrhoeae may have been a relatively easy, albeit  a rather 
uncomfortable discharge of ones duties. The preservation of other diseases such as 
Kuru required brains, a strong stomach, and questionable ethics. One could argue 
of course, that not all the species Noah preserved were intended to survive the 
great flood. There may have been one or two hitchhikers who slipped onboard 
unnoticed, right under Noah’s nose. 
 
The bacterium Staphylococcus aureus can be found living happily, amongst other 
places, in the nasal passages of humans.  S. aureus is responsible for a range of 
medical conditions ranging from minor skin infections, such as pimples, to more 
serious conditions including pneumonia, and septicemia. If the story of Noah is 
true, then the strain of S. aureus that slipped onboard the Ark was no ordinary 
bacterium. This strain was a methicillin-resistant Staphyloccocus aureus (MRSA) 
which, somehow, had achieved resistance to all know penicillins of the 20th 
century. Some of these penicillins are completely unnatural, produced in a 
laboratory by semi-synthesis. This begs the question: how could a bacterium 
residing in Noah’s nose achieve resistance to the semi-synthetic penicillin’s of the 
20th century, some 4000 years prior to their creation? 
 
Indeed, it might be difficult to believe that all the MRSA alive today are direct 
descendants from the bacteria in Noah’s nose after a lengthy excursion at sea. 
Perhaps we should turn to the wisdom of another seafaring man, who undertook an 
even longer expedition on HMS Beagle. Charles Darwin, like Noah, also had an 
interest in animals and plant species. If we take on board Mr. Darwin’s theory of 
evolution through natural selection, then perhaps we might be forced to conclude 
that the phenomenon of bacterial resistance to antibiotics actually represents living 
proof of his theory; that antibacterial resistance to antibiotics is still, unfortunately, 
a case of evolution in action.  
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1 Introduction 
Imagine how your life would have been without being able to turn to the aid of 
antibiotics; how a case of pneumonia could be fatal, or how a simple cut while 
shaving could turn into lethal septicemia. For my generation it is difficult to 
imagine, almost unfathomable. Even for my parents’ generation, who were born at 
a time when the commercial production of penicillin was being developed, 
antibiotics have always been a magic bullet, killing the microbes without poisoning 
the infected individual. Yet if we go back to my grandfather’s generation there 
were no antibiotics, no miracle cures. Treatments involved the use of poisons like 
strychnine, or arsenic, and the use of antiseptics. Unfortunately for my grandfather, 
who succumbed to tuberculosis, streptomycin had not yet become available.  
 
The word antibiotic is derived from the Greek anti (against) and bios (life). Paul 
Vuillemin, a pupil of Louis Pasteur, coined the term ”antibiosis” in 1889 to 
describe the process by which life could be used to destroy life. However, it was 
Selman Waksman who coined the term ”antibiotic” in 1945.  Originally the term 
only applied to compounds derived from living organisms capable of killing or 
inhibiting bacterial growth.  The term has now been expanded to include synthetic 
antimicrobial drugs as well. Natural antibiotics belong to the group of compounds 
known as secondary metabolites. They are generally produced at low specific rates, 
and are not considered essential to the organism producing them, at least in pure 
culture. In their natural environment these antibiotics are essential to the organisms 
that produce them. Antibiotics can be considered the chemical weapons of the 
microbial world, were they are used for the survival and competitive advantage 
within the microenvironment (Demain & Fang, 2000). 
 
When antibiotics, such as penicillin, were first introduced in the 1940’s a victory 
was declared against infectious disease.  A panacea had been found, which would 
change the way humans thought about infectious disease.  The free love movement 
of the “swinging sixties” might not have been so free if it weren’t for the relatively 
simple treatment of many sexually transmitted diseases with antibiotics.   
Unfortunately the euphoria of the antibiotic “magic bullet” has dissipated.  The 
huge consumption of antibiotics, and their widespread use, and abuse, has lead to 
the concomitant emergence of bacterial resistance to antibiotics. Over-optimism 
and complacency in the pharmaceutical industry, even as recently as the 1980’s, 
saw little development towards new antibiotic drugs.  At the same time the spread 
of antibiotic resistance has accelerated.  This has lead to the re-emergence of 
diseases once controlled, such that bacterial infections represent, once again, one 
of the greatest threats to human health (Cohen, 2000). 
 
In order to address the problem of antibiotic resistance in bacteria we must first 
understand how antibiotics work, and the mechanisms bacteria employ in order to 
avoid their effects. 
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1.1 A Brief History of Antibiotics 
Although the name “Alexander Fleming” is synonymous with penicillin and 
antibiotics, he was certainly not the first person to observe the inhibition of 
bacterial growth by fungi.  The antibacterial properties of various moulds have 
been used since the times of ancient Greece and China, and Russian peasants were 
known to use warm soil as a treatment for wounds.  However, primitive technology 
did not permit the isolation of the active compounds to improve their efficiency.   
 
The use of antibiotics in modern medicine perhaps began with Joseph Lister, who 
in 1871 used mould contaminated urine to treat infected wounds.  His inspiration 
was Sir John Scott Burdon-Sandersson, who observed that bacteria were unable to 
grow in culture fluid covered with mould. Lister also went on to describe the 
antibacterial action of Penicillium glaucum, a fungus used in French blue cheese 
production. Six years later Louis Pasteur and Jules Joubert observed the inhibition 
of growth of anthrax bacteria using soil microorganisms (Pasteur & Joubert, 1877), 
while E. von Freduenreich observed the antibacterial properties of culture filtrates 
from Pseudomonas aeruginosa (Freduenreich, 1888). In 1897 the thesis of medical 
student Ernest Duchesne described the partially purification of a compound from a 
Penicillium mould which he used to cure a guinea pigs of typhoid. The Pasteur 
Institute ignored his results, and Duchesne’s achievements passed into obscurity 
after his early death. It is interesting to note that penicillin is ineffective against 
typhoid. The mould used by Duchesne was not preserved, and thus we will never 
know which species, or antibiotic, he had discovered. 
 
In the early 1920’s Andre Gratia and Sara Dath observed that their Staphylococcus 
aureus cultures were inhibited by fungal contamination. They successfully 
identified the species as a Penicillium, but they did not pursue a further 
investigation of the moulds antibacterial properties. Around the same time 
Alexander Fleming observed the weak antibacterial effect of lysozyme. It was not 
until 1928 when Fleming made his serendipitous observation while looking 
through old culture plates of S. aureus. Fleming observed that bacterial growth was 
inhibited around a contaminating mould, and the subsequent isolation of the mould 
demonstrated that it was Penicilium notatum. The antibacterial agent was named 
penicillin (Fleming, 1929), although Fleming’s attempts to isolate the active 
compound proved unsuccessful, with his work remaining largely unnoticed for 
another nine years. 
 
It was not long after Fleming’s discovery the first successful oral antibiotics were 
introduced. Gerhard Domagk had discovered the antibacterial properties among 
certain dyes, one of which was a sulfonamide with the trade name prontosil. The 
synthetic sulfonamides played a central role in preventing infection during World 
War II.  It was the German discovered sulfonamides, and not English penicillin, 
which cured an ill Winston Churchill in Carthage, Tunisia, in 1943, despite reports 
to the contrary by the British press. Incidentally, at the same time of Domagk’s 
discovery, a chemist by the name of Ernst Chain left Germany to work in Oxford.  
Chain was soon to become intertwined in the penicillin success story.  
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Throughout the 1930’s Fleming continued to work on penicillin. Initial tests were 
inconclusive, but this was due to its use as an antiseptic. In 1933 disaster struck, 
when fellow rifle club member, and team captain, Keith Rogers contracted 
conjunctivitis during a competition. Fleming made a penicillin ointment, cured his 
captain, and the match was won. More importantly Fleming had won over any 
doubts that penicillin would be unsuitable for clinical use.   
 
In 1938 in Oxford, Howard Florey, who had previously worked with lysozyme, 
read Flemings paper, and tried to purify three promising substances. One of these 
substances was penicillin. Ernst Chain and Norman Heathley determined how 
penicillin could be isolated and concentrated, as well as correctly predicting its 
structure, and by 1940 the Oxford team was able to produce enough penicillin to 
begin testing. With World War II raging the development and production of 
penicillin continued in the USA. Fleming’s original strain only produced trace 
amounts of penicillin, insufficient for large-scale production, however a mould 
isolated from a rotting cantaloupe in a Peoria market (Raper, 1946) proved a 
serendipitous ally, capable of producing up to 60 µg ml
-1 penicillin. Thus began a 
history of ‘strain improvement’ through brute force genetic manipulation, 
eventually leading to the ‘Wisconsin family’ of superior strains, some of which 
produced over 1800 µg ml
-1 (Backus & Stauffer, 1955). By 1945 the problems 
with rapid secretion in the urine had been overcome, and with advances in 
production and semi-synthesis, penicillin was successfully mass-produced. 
 
Around the same time Selman Waksman discovered streptomycin, which 
represented a new class of antibiotics. The mechanism by which streptomycin 
inhibits bacteria growth is quite different to that of penicillin, and it later proved 
successful in the treatment of tuberculosis.  Since then a plethora of antibacterial 
agents belonging to different antibiotic classes have been identified. 
 
1.2 Antibiotic Classes 
Antibiotics can be organized into different classes according to their effect and 
mode of action. Their effect is either bactericidal or bacteriostatic, where the 
former kills the bacteria, and the latter inhibits the growth of the bacteria, allowing 
the immune system to deal with the infection. Antibiotics can be described as 
possessing different “spectra of activity”, where “broad spectrum” antibiotics are 
effective against a large number of infectious bacterial species.  The opposite is 
true for narrow-spectrum antibiotics, which are only active against a specific 
family, or genus of bacteria.  The different classes of antibiotics, their effect on 
bacteria and principal mechanisms have been summarized in Table 1.   14
 
Table 1 Representative classes of antibiotics, their effect, and mode of action. 
Class Effect 
a Action 
Aminocyclitols b.s  Protein  synthesis 
Aminoglycosides b.c  Protein  synthesis 
β-lactams   b.c Cell  wall 
Fluoroquinolones b.c  Genetic  replication 
Lincosamides b.s  Protein  synthesis 
Macrolides b.s  Protein  synthesis 
Sulfonamides b.s  Metabolic  processes 
Tetracyclines b.s  Protein  synthesis 
Phenicol b.c  Protein  synthesis 
a.  The effect of antibiotics defined as either bacteriostatic (b.s) or bacteriocidal (b.c). 
 
1.2.1 β-Lactam Antibiotics 
Penicillin belongs to the class of β-lactam antibiotics. The β-lactams possess a 
bactericidal effect, except against Enterococcus sp., where they act as a time 
dependent killer. They are among the most successful antibiotics, and account for 
60-65% of the total world market, generating revenues in the order of $US 15 - 23 
billion, per annum (Demain & Elander, 1999; Elander, 2003). 
 
The  β-lactam antibiotics share a common chemical motif, which consists of a 
strained, four-membered, heterocyclic ring, known as the β-lactam ring. The β-
lactam ring is typically fused to a second ring forming a bicyclic ring structure. The 
second ring may be five-membered (penam/penem) or six-membered 
(cepam/cephem), where the nomenclature used reflects the ring saturation (Figure 
1.1). 
 
   
Figure 1.1 Structure of the β-lactam ring, the common motif of the ß-lactam antibiotics, and 
the nomenclature of the second ring fused to the β-lactam ring 
 
The  β-lactams can be sub-divided in to a number of different groups, in part 
defined by the chemistry of the second ring, and by group substitution on the 
heterocyclic ring. Significant variation can be found in the chemical structures of 
the different β-lactams. Such variation is important as it creates a range of 
characteristics defining the physical properties of the antibiotic, e.g. solubility, 
stability, as well as the spectrum of activity. While some of these variations are 
synthesized naturally, many are introduced through the methods of semi-synthesis 
of fermented compounds.    15 
 
1.2.2 Penicillin; the First β-Lactam Antibiotic 
Although Chain and Abraham had predicted the structure of penicillin it was the 
pioneering work of Dorothy Crowfoot Hodgkins who determined the three 
dimensional structure of penicillin using X-ray crystallography (Crowfoot et al., 
1949). The penicillins consist of a bicyclic ring, where the β-lactam ring is fused to 
a five-membered thiazolidine (penam) ring containing a sulphur atom  (Figure 1.2).  
The bicyclic rings are arranged such that they possess 3R,5R stereochemistry. The 
penicillin nucleus consists of 6-aminopenicillanic acid (6-APA), which can be 
modified at the R1 position to introduce a range of different side chains of different 
chemical properties. More recently advances in the chemical synthesis now permit 
the synthesis of a number of other bicyclic β-lactam penams/penems, (see section 
1.2.4). 
 
 
 
Figure 1.2 The structure of the benzylpenicillin (PenG).  The penicillin 6-APA core is 
shown in black, while the R1 group is shown in light grey.  The numbering of the carbons 
across the bicyclic ring is shown.  
 
1.2.3 Cephalosporins - 1
st to 4
th Generation 
Not long after the successful mass production of penicillin, a new β-lactam 
antibiotic was discovered. Cephalosporins were produced by a fungus originally 
identified at in a Sardinian sewer (Brotzu, 1948), and showed increased activity 
towards Gram-negative bacteria. The cephalosporins differ from the penicillins in 
that the β-lactam ring is fused to a six-membered (cephem) dihydothiazine ring 
(Figure 1.3). The expansion of the five-membered ring to a six-membered ring also 
affords an increased resistance against bacterial β-lactamases (see section 1.4). The 
cephalosporin nucleus consists of 7-aminocephalosporanic acid (7-ACA), which 
can be modified at the R1 and R2 positions to produce a variety of different 
cephalosporins.  
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Figure 1.3 Structure of cephalosporin C.  The 7-ACA nucleus is shown in black, while the 
R1 and R2 groups are shown in light grey.  The numbering of carbons across the bicyclic 
ring is shown. 
 
Both penicillin and cephalosporin C were isolated from filamentous fungi, e.g. 
Penicillium chrysogenum or Cephalosporium acremonium. However, the synthesis 
of  β-lactam antibiotics is not exclusively limited to fungi. Bacteria, such as 
Streptomyces  clavuligerus and Amycolatopsis  lactamdurans, are capable of 
producing an even broader range of β-lactam antibiotics. It is these “bacterial 
antibiotics” which helped to give rise to new generations of cephalosporins. 
 
The cephalosporins can be subjectively divided into “generations” based on their 
antimicrobial activity and resistance to β-lactamases. In general each successive 
cephalosporin generation is less active against Gram-positive bacteria, however the 
activity against Gram-negative bacteria has increased, particularly against aerobes. 
Their discovery was an important solution to the emerging problem of bacterial 
resistance to penicillins.   
 
For historical reasons the cephamycins and carbacephems  have been classified 
with the second generation cephalosporins, although technically speaking they are 
not cephalosporins, since they lack the 7ACA core. However, like the 
cephalosporins they consist of a β-lactam ring fused to a cephem ring. In the 
carbacephems a carbon is substituted for the sulphur at position 1, while the β-
lactam ring of the cephamycins has a methoxyl group at the C7-position (see 
Figure 1.4). The third generation cephalosporins include the oxacephems, although 
they are sometimes regarded as fourth generation antibiotics. In the oxacephems 
oxygen is substituted at position 1 of the cephem ring instead of carbon or sulphur. 
The fourth generation cephalosporins show an extended spectrum of activity, with 
increased activity towards bacterial β-lactamases. 
   17 
 
 
Figure 1.4 Core structures of cephamycins, carbacephems, and oxacephems representing the 
second and third generation cephalosporins. Note that the cephem ring of carbacephems and 
oxacephems may also be saturated resulting in the carbacephams or oxacephams, 
respectively. 
 
1.2.4 Other β-Lactams 
Other  β-lactam structures have been isolated and characterized from bacterial 
sources.  These include the monolactams, penems and carbapenems (Figure 1.5), 
as well as the clavams (Figure 1.6). The monolactams represent perhaps the most 
literal definition of a β-lactam antibiotic, consisting of a naked β-lactam ring. A 
second ring may be present as the R1 or R2 side chains, e.g. the side-chain of the 
monobactam Aztreonam (see Figure 1.5). 
 
The core penem structure resembles penicillin, except the second ring possesses an 
unsaturated penem ring, and the R1 side chain has moved to the C2 position of the 
penem ring. In the carbapenems, the sulphur at position one of the penem ring is 
substituted for a carbon atom.  Using chemical synthesis it is possible to replace 
the sulphur at position one in a penem/penam ring with selenium, nitrogen, or 
oxygen giving rise to selenapenams, azapenams or oxapenems, respectively. Of all 
the β-lactam antibiotics, it is the carbapenems that possess the broadest spectrum 
activity (Kropp et al., 1985).   
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Figure 1.5 Examples of the monolactams (Aztreonam), penems (Faropenem) and 
carbapenems (Imipenem).  The core structure is shown in black, and the R1 and/or R2 side 
chain in grey.   
 
The clavam nucleus is also similar to that of penicillin, except that the penam ring 
contains oxygen instead of sulphur at position one. The R1 side chain is located off 
the C2 position on the penam ring, with an additional R2 side chain at the C3 
position. Unlike the other β-lactams, the clavams show variation in the 
stereochemical arrangement of the penam ring with respect to the β-lactam ring 
(Figure 1.6). The significance of this stereochemical difference is discussed later in 
section 1.6). 
 
 
 
Figure 1.6. The stereochemical arrangement of the bicyclic rings in 3R,5R-clavulanic acid 
and 3S,5S-clavaminic acid. The hydrogen of the C5 carbon can be either pro-R or pro-S. 
Likewise the stereochemistry of the C3 carboxyl group can be pro-R or pro-S. The clavam 
R1 side-chain is shown in grey. 
 
1.3 Mechanism and Action of β-Lactam Antibiotics 
The β-lactam antibiotics act by interfering with the enzymes involved in the growth 
of the bacterial cell wall, and only exert a bactericidal effect on growing cells. The 
cell wall not only determines the shape of the organism, but also protects it as well. 
The cell wall is composed of, amongst other things, a peptidoglycan layer which 
forms a crystalline lattice. The peptidoglycan layer is formed from linear chains of 
two alternating amino sugars, N-acetyl-glucosamine (NAG) and N-acetyl-muramic 
acid (NAM). The NAM/NAG-peptide subunits are then cross-linked together by a 
short amino acid chain containing D-alanine, D-glutamine and 
mesodiaminopimelic acid (or lipid II), although the composition varies between   19 
species. The final transpeptidation step is facilitated by membrane bound DD-
transpeptidases, also known as penicillin binding proteins (PBPs) (Fig 1.7a). The 
β-lactam antibiotics are analogues of D-alanyl-D-alanine, and thus act as pseudo-
substrates of the PBPs. Once bound in the active site the β-lactam ring is 
hydrolysed, acylating the active site serine to form a stable covalent acyl-enzyme 
complex (Fig 1.7b). 
 
 
 
Figure 1.7 The reaction catalysed by PBPs, and their inhibition by β-lactam antibiotics. (A) 
The transpeptidase reaction catalysed by PBPs. (B) The inhibition of PBPs by β-lactam 
antibiotics. The structural analogy between D-Ala-D-Ala and the β-lactam antibiotics are 
shown with a grey box. 
 
For a long time it was thought that the inactivation of the PBP prevented the cross-
linking of the NAG/NAM subunits in the peptidoglycan layer, in turn weakening 
the cell wall, eventually leading to bacteriolysis (Tipper & Strominger, 1965). 
However the lysis of the bacterial cell wall has been shown to be enzymatically 
mediated (Rogers & Forsberg, 1971; Tomasz et al., 1970). Thus, while the 
inhibition of the cell wall construction results in the lysis of the cell, the mechanism 
by which the cell dies is not fully understood (Bayles, 2000). 
 
1.4 Mechanisms of Bacterial Resistance to β-Lactam Antibiotics 
Almroth Wright, whom Fleming worked for at St Marys, had predicted bacterial 
resistance to penicillin, even before it was observed in some strains of E. coli 
(Abraham & Chain, 1940). By the 1950’s resistance to penicillin in 
Staphylococcus had become a major problem, and today once a drug enters 
widespread therapeutic use, the clock is ticking. 
 
Bacterial resistance to antibiotics illustrates a wonderful, if not irksome example of 
evolution through mutation and (un)natural selection. Given the large number of 
bacteria in an infection cycle, and an intrinsic mutation rate of ca. 10
7 it is only a 
matter of time before a mutation inexorably arises conferring some form of 
resistance. The resistant mutant soon becomes the dominant variant in the bacterial   20
population, especially if the antibiotic is given at sub-therapeutic levels, since the 
survival of the resistant bacteria is almost guaranteed. Many of the genes 
conferring antibiotic resistance are borne on plasmids, which can be rapidly spread 
between bacterial cells and species. The activity of transposons’ can later lead to 
the incorporation of the resistance genes into the bacterial genome. 
 
1.4.1 Resistance by Modifying Existing Systems 
There are several different mechanisms by which bacteria can protect themselves 
against antibiotics (Poole, 2004; Walsh, 2000), where more than one may be 
simultaneously employed. General mechanisms, such as improved efflux pumps, 
prevent the accumulation of therapeutic drug levels within the cell. Similarly, the 
channels in the outer-membrane formed by porins can be altered, changing the 
permeability of the membrane, thus preventing the antibiotic from accumulating in 
the cell. Such mechanisms can be effective against antibiotics from different 
classes, targeting different processes, e.g. tetracyclines (protein synthesis) and β-
lactams (cell wall synthesis). Alternatively, the target of the antibiotic can also be 
modified, or “reprogrammed”, in order to reduce its susceptibility to the drug. For 
example, mutations in the active site of a PBP has resulted in a β-lactam antibiotic-
insensitive transpeptidase (Mainardi et al., 2002). 
 
1.4.2 Protein Mediated Destruction of the β-lactam ring  
The most prevalent mechanism of antibiotic resistance employed by bacteria 
involves the enzymatic destruction of the β-lactam ring by a group of enzymes 
known as β-lactamases (penicillinases). Thus, while the β-lactam ring acts as a 
champion inhibiting PBPs, it is also the Achilles heal when challenged by β-
lactamases. The β-lactamases are structurally related to PBPs (Massova & 
Mobashery, 1998), and are capable of hydrolysing the β-lactam ring (Figure 1.8); 
thus they are potentially active upon a number of different β-lactam antibiotics. 
Secreted into the periplasm these enzymes can destroy the β-lactam antibiotics 
before they can even reach their target. 
 
 
Figure 1.8 The hydrolysis of the labile acyl-enzyme complex catalysed by a serine β-
lactamase. 
 
The  β-lactamases have been classified according to their sequence similarities, 
substrate preference, and whether they are encoded for by genes on a plasmid or 
chromosome. They can also be classified by their mechanism of action, such that 
class A (penicillinases), class C (cephalosporinases) and class D (oxacillinases) β-
lactamases are metal-independent enzymes, utilizing a catalytic serine. The class B 
(metallo-eznymes) enzymes employ a metal ion, e.g. Zn
2+, at their active site, and   21 
can be inhibited by chelating agents. Despite the growing importance of metallo-ß-
lactamases, it is the serine β-lactamases that represent the greatest clinical 
challenge. The classical extended-spectrum-β-lactamases, which have evolved 
from class A TEM and SHV enzymes, represent the most prevalent types, with 
over 150 TEM/SHV-derived enzymes reported. 
 
1.5 How to Combat Antibiotic Resistance? 
Answering the above question with a pithy “Stop using antibiotics!” might be 
considered a stupid reply by some people. Then again, if you consider that the 
problem of bacterial antibiotic resistance arose due to our wide spread use/abuse of 
antibiotics, then removing the selection pressure would relieve the need for 
bacteria to evolve mechanisms to circumvent the effect of antibiotics. Of course, 
such a solution would be rather impractical. If we elect to stop using antibiotics our 
fate would be the same as if we continued to over-use antibiotics, i.e. we are left 
with no effective treatment against infectious bacteria, a situation reminiscent of 
the pre-1930’s. So how can we rationally approach this problem of antibiotic 
resistance? 
 
A less extreme strategy is to extend the lifespan of current antibiotics by restricting 
their use. In the developed world it has been estimated that 50% of prescribed 
antibiotics are for viral infections, which do not respond to antibiotics. In some 
developing countries antibiotics can be obtained without prescription at the 
pharmacy, in others, drug availability is limited and of dubious quality or potency. 
Either way this tends to create a strong tendency towards self-medication, resulting 
in sub-therapeutic doses of antibiotics; an outstanding method for selecting drug 
resistant bacteria. Restricting the use of antibiotic not only applies to humans. Take 
for example the consumption of the antibiotic vancomycin in Denmark in 1994; the 
human consumption (24 kg) was dwarfed by the amounts used for animal health 
(24,000 kg). Thankfully, as of the first of January, 2006, the EU has banned the use 
of antibiotics for growth promotion in animal feed.  Unfortunately, the situation 
appears unlikely to be mirrored in the U.S.A, where such practice is widespread 
and encouraged. 
 
Simultaneously, the development of new antibiotic classes will provide new 
treatment against the current multi-resistant bacteria. The use of genomics may 
help in the identification of essential bacterial genes, which are appropriate targets 
for inhibition by new drugs. For example, the enzyme peptide deformylase is an 
essential gene in many bacteria, to which new potent inhibitors have been 
developed (Chen et al., 2000).  
 
Another strategy involves the development of new antibiotics, which circumvent 
resistance by targeting the mechanisms of resistance, e.g. β-lactamases. In order to 
combat β-lactamase mediated resistance two strategies have been used. The first 
involves the modification to the β-lactam core, or variation in the R1/R2 side-
chains. In this way the antibiotic is no longer recognized by the β-lactamase. These 
modifications can be achieved using chemical modifications via semi-synthesis, or 
by the identification and development of new antibiotic compounds amongst the   22
secondary metabolites of other bacteria. Unfortunately, only a few amino acid 
substitutions, at a limited number of positions, are required before resistance is 
once again acquired. Like the PBPs, the β-lactamases are capable of 
altering/expanding their binding sites, to allow the binding of the bulky oxyimino 
side-chains of broad spectrum β-lactams, resulting once again in the hydrolysis of 
the β-lactam antibiotic. 
 
An alternate strategy involves the development of β-lactamase inhibitors. Some 
compounds possess both antibiotic and β-lactamase inhibitory properties, e.g. 
broad-spectrum carbapenems. Others are potent β-lactamase inhibitors, but lack 
sufficient antibacterial activity per se, and are therefore administered in 
combination with more potent antibiotics. The use of such inhibitors potentially 
allows the use of β-lactam antibiotics to which bacteria have previously developed 
resistance, since the inhibitor effectively “knocks out” the bacterial resistance 
mechanism. Several serine β-lactamase inhibitors are in clinical use, e.g. see Figure 
1.13. Of these two are unnatural compounds (sulbactam and tazobactam) produced 
by semi-synthesis.  A third inhibitor, and by far the most common, is clavulanic 
acid, which is produced by anaerobic fermentation of the actinomycete, 
Streptomyces clavuligerus.  
 
 
Figure 1.9 The structure of some of the serine ß-lactamase inhibitors in clinical use. 
 
1.6 The β-Lactamase Inhibitor Clavulanic Acid 
As mentioned previously, the clavams can be classified according to the 
stereochemical arrangement of their bicyclic ring, i.e. the position of the C5 
hydrogen can be either pro-R or pro-S (see Figure 1.10). The X-ray structure of 
clavulanic acid (Brown et al., 1984; Howarth et al., 1976) reveals that the β-
lactamase inhibitor possesses 3R,5R stereochemistry across the strained bicyclic 
ring, which it shares with penicillins. In this respect clavulanic acid acts as a very 
slow substrate for β-lactamases. On the other hand, the 5S-clavams do not show β-
lactamase inhibitory activity, although several possess antibacterial and antifungal 
activity (Baggaley et al., 1997). Because the stereochemistry of the 5S-clavams is 
different to that of clavulanic acid and the other β-lactam antibiotics, the 
mechanism by which the 5S-clavams inhibit bacterial growth is also different. For 
example, valclavam and hydroxyethylclavam act by the non-competitive inhibition 
of bacterial homoserine-O-succinyl transferase (Röhl et al., 1987).  
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Figure 1.10 The structure of (3R,5R)-clavulanic acid, and the antibacterial (5S)-
alanylclavam, which demonstrate the two different stereochemical arrangements of the 
oxazolidinic ring in clavams. Note that the C3 side chain is absent in the 5S-clavams, which 
possess antibacterial activity. 
 
1.6.1 Mechanism of ß-Lactamase Inhibition by Clavulanic Acid. 
Clavulanic acid, or clavulanate, (Figure 1.10) is a weak antibiotic, but a potent 
inhibitor of class A, and some class D, serine β-lactamases. It acts as a pseudo-
substrate, occupying the active site of the β-lactamase for sufficiently long time to 
prevent the degradation of co-administrated β-lactam antibiotics. At higher 
concentrations, e.g. at 115 fold excess, clavulanic acid binds irreversibly (Fisher et 
al., 1978) to the β-lactamase through a complex mechanism which results in the 
formation of a stable acyl-enzyme complex (Brown et al., 1996) shown 
schematically in figure 1.11. 
 
The binding of clavulanic acid to SHV-1, a typical class A serine β-lactamase, is 
coordinated in part by the hydrogen bonding of the C7 carboxyl group of 
clavulanic acid to the catalytic serine (Ser70) and a main-chain nitrogen, e.g. 
Ala
237, in an “oxyanion hole”. This subsequently leaves the carbonyl carbon (C7) 
vulnerable to nucleophillic attack by Ser
70, resulting in the formation of a covalent 
acyl-intermediate, and the opening of the β-lactam ring. This is followed by the 
opening of the five-membered oxazolidinic ring, resulting in the linearization of the 
inhibitor, as an imine intermediate. The imine intermediate subsequently undergoes 
isomerization, resulting in the formation of a cis-enamine, which can isomerise to 
the more stable trans-enamine (Figure 1.11). After several hours the enzyme is 
irreversibly inhibited via the covalent acylation at Ser
130 (Chen & Herzberg, 1992; 
Padayatti et al., 2005). 
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Figure 1.11 A general scheme demonstrating the complexity of the inhibition of β-
lactamases by clavulanic acid, adapted from Padayatti et al. (Padayatti et al., 2005). 
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2 β-Lactam Biosynthesis in Streptomyces 
clavuligerus  
Take a deep breath next time you are outdoors after it has been raining. Can you 
“smell” the rain? That smell is created by the spores of the Actinomycetes. The 
Actinomycetes are a group of Gram-positive bacteria found inhabiting the soil, and 
are renowned for their ability to produce secondary metabolites of pharmaceutical 
interest. Members of the genus Streptomyces account for approximately 70–80% of 
the production of potential pharmaceutical compounds. The species Streptomyces 
clavuligerus is of particular interest, as it produces several β-lactam compounds. 
Initially described as a cephamycin C producing species (Higgens & Kastber, 
1971; Nagarajan et al., 1971), it also produces deacetylcephalosporin C, as well as 
different clavam compounds, including the medicinally important β-lactamase 
inhibitor clavulanic acid (Brown et al., 1976). 
 
The ability to synthesize clavams is confined to the genus Streptomyces, with the 
production of clavulanic acid restricted to only four species, S. clavuligerus, S. 
jumonjinensis,  S. katsurahamanus and one unidentified species. S. lipmanii 
produces many of the intermediates involved in clavulanic acid biosynthesis, but 
does not produce the inhibitor itself. It is interesting to note that the species 
producing clavulanic acid also produce cephamycin C, and that none of the 
actinomycetes produce clavulanic acid alone (Challis & Hopwood, 2003). This 
situation is mirrored in the clinical application of clavulanic acid, which is co-
administered with more potent antibiotics, e.g. Augmentin ™(amoxicillin and 
clavulanic acid). 
 
Only two Streptomyces genomes have been sequenced, S. coelicolor (A3) (Bentley 
et al., 2002) and S. avermitilis (Ikeda et al., 2003), although neither of these 
species produce clavulanic acid. The sequencing reveals a large genome, by 
bacterial standards (8.8 Mbp and 9.0 Mbp, respectively). The protein coding 
sequences (ORFs) are typified by possessing a high G + C content (>70%). 
Approximately 4.5% and 6% of the genes are predicted to involved in the 
production of secondary metabolite, where these genes are often arranged in 
clusters. 
 
2.1 Arrangement and Regulation of the Cephamycin 
C/Clavulanic Acid Super Cluster 
In S. clavuligerus the genes for the biosynthesis of cephamycin C and clavulanic 
acid are arranged in a super cluster (Figure 2.1). The cluster includes genes for the 
biosynthesis of the β-lactam compounds, as well as accessory genes. The latter are 
responsible for gene regulation within the super cluster, the export of the β-lactam 
compounds from the cell, as well as conferring self-resistance. Furthermore, 
several genes involved in the early biosynthetic steps of clavulanic acid are 
duplicated. A gene cluster containing a minimum of four genes homologous to 
ceaS,  bls,  pah and oat (Jensen et al., 2004b; Tahlan et al., 2004b) is located   26
elsewhere in the genome. This paralogous gene cluster is differentially regulated, 
and only expressed in soy growth medium (Tahlan et al., 2004a), as opposed to 
starch asparagine medium.. In addition, a homologue to cas2 is located elsewhere 
in the genome (Marsh et al., 1992), and is flanked by genes associated with the 
production of other 5S-clavams metabolites (Mosher et al., 1999). 
 
 
 
Figure 2.1 The arrangement of genes within the cephamycin C/ clavulanic acid super 
cluster, where pcbR is shown in common to both the cephamycin C and clavulanic acid 
gene clusters. The paralogous gene cluster of the early clavulanic acid genes is shown, as 
well as the cas2 homologue flanked by the cvm genes important to 5S-clavam biosynthesis. 
Note that the cluster is not drawn to scale. 
 
The life cycle of Streptomyces sp. involves a number of morphological changes, 
and the production of secondary metabolites, including antibiotics, are associated 
with these changes. The life cycle starts with the germination of a spore to produce 
hyphal filaments, which form an elongated and repeatedly branched network. This 
creates a flat colony of multinucleoid hyphae, known as the substrate mycelium. 
After several days, the substrate mycelium produces aerial hyphae, which stand up 
in the air, forming a white fuzzy layer on the mycelium. The aerial hyphae undergo 
extensive cellular division, eventually dividing into uni-nucleoidal compartments, 
which then mature into a spore.  
 
The morphological processes of aerial hyphae production appear to be initially 
regulated by the Bld genes. Mutants of these genes are unable to produce aerial 
hyphae, nor spores, and are thus described as possessing a ”bald” (bld) phenotype. 
Initially identified in S. coelicolor, several Bld genes have been identified in S. 
clavuligerus, including BldA and BldG. Both bldA and bldG mutants possess a 
bald phenotype (Bignell et al., 2005; Trepanier et al., 2002), however the bldG 
mutant is completely blocked in the synthesis of clavulanic acid, 5S-clavams (e.g.   27 
clavam-2carboxylate and alanylclavam) as well as cephamycin C. The BldG gene 
is thought to encode an anti-anti-sigma-factor (Bignell et al., 2000), regulating the 
activity of a target sigma-factor. BldG appears to act upstream of the CcaR 
transcriptional activator of cephamycin C and clavulanic acid biosynthesis (Perez-
Llarena et al., 1997). CcaR is located in the cephamycin C gene cluster and 
encodes a protein with similarity to ompR DNA regulatory proteins, binding to the 
bidirectional promoter of cefD and cmcI in the cephamycin C gene cluster 
(Santamarta et al., 2002) Furthermore, CcaR binds to the promoter of ClaR in the 
clavulanic acid gene cluster, which in turn encodes a protein with homology to the 
LysR-type DNA regulatory proteins. ClaR is a transcriptional activator of the genes 
within the clavulanic acid gene cluster including itself. Mutants of ClaR produce 
penicillin/cephamycin, but do not produce clavulanic acid. The genes involved in 
the biosynthesis of early intermediate are expressed normally in the claR mutant 
(ceaS, bls, pah, cas), while genes upstream in the cluster are not expressed e.g. 
orf7, ClaR, cad, orf10 (Jensen & Paradkar, 1999). A more detailed understanding 
of the processes involved in the genetic regulation the β-lactam antibiotic genes in 
S. clavuligerus is still required. 
 
2.2 Biosynthesis of Penicillin N, Cephalosporin C and 
Cephamycin C 
Penicillin N, cephalosporin C and cephamycin C share a common biosynthetic 
origin. The pathway is summarized in Figure 2.2.  L-α-aminoadipic acid (L-α-
AAA), L-cystein, and L-valine are condensed to form δ(L-α-aminoadipyl)-L-
cysteinyl-D-valine (ACV), where L-valine undergoes a configurational inversion as 
part of the reaction. The condensation of these amino acids is catalysed by a single 
multifunctional enzyme, ACV synthase, in an Mg
2+ /ATP–dependent reaction 
(Byford et al., 1997). ACV is then cyclised by isopenicillin N synthase (IPNS), 
which catalyses the formation of the β-lactam ring. IPNS is an iron (II) oxygen-
dependent enzyme, catalysing the removal of four electrons and four hydrogens 
from ACV, to form water and isopenicillin N. Isopenicillin N serves mainly as a 
precursor for penicillins as well as cephalosporins and cephamycins, although it 
does possess weak antibacterial activity itself. 
 
In the fungi producing only penicillin (e.g.  Penicillium chrysogenum) the final 
reaction is catalysed by acyl coenzyme A:isopenicillin N acyltransferase (IAT) 
(Tobin et al., 1990). An equivalent enzyme has not been identified in bacteria. The 
enzyme IAT catalyses the removal of the hydrophilic L-α-AAA side chain, in 
exchange for a hydrophobic acyl group. Since the substrate specificity of IAT is 
rather unspecific (Luengo, 1995) the synthesis of particular penicillins can be 
directed by the addition of appropriate precursor molecules during fermentation, 
e.g. phenoxyacetic or phenylacetic acid to produce penicillin V or penicillin G. 
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Figure 2.2 The biosynthetic pathway of penicillin N, cephalosporin C and cephamycin C in 
Streptomyces clavuligerus. The enzymes catalysing the reactions (and the genes encoding 
them) are shown. 
 
Isopenicillin N serves as the branch point between penicillins and cephalosporins, 
where the enzyme isopenicillin epimerase is responsible for the conversion of 
isopenicillin N to penicillin N (Jensen et al., 1983). The five membered   29 
thiazolidine ring of penicillin N undergoes expansion to create the six-membered 
dihydrothiazine ring of deacetoxycephalosporin C (DAOC). DAOC is 
subsequently hydroxylated at the C-3’ position to form deacetylcephalosporin C 
(DAC). In prokaryote cephalosporin producers, e.g. S. clavuligerus, these reactions 
are performed by two separate enzymes (Jensen et al., 1985), such that 
deacetoxycephalosporin C synthase (DAOCS) expands the thiazolidine ring and 
deacetylcephalosporin C synthase (DACS) hydroxylates the C-3’ position. In 
eukaryotic cephalosporin producers, e.g. Cephalosporium acremonium, both steps 
of the reaction are catalysed by the bi-functional enzyme 
deacetoxy/deacetylcephalosporin synthase (DAOCS/DACS). The enzymes 
catalysing the conversion of penicillin N to DAC, i.e. DAOCS/DACS, DAOCS 
and DACS, are all Fe(II), 2-oxoglutarate-dependent dioxygenases (2ODDs).  
 
The final step of cephalosporin C synthesis is assisted by acetyl-CoA:DAC 
acetyltransferase (Brakhage, 1998), which catalyses the transfer of an acetyl moiety 
from acetyl-CoA to the hydroxyl group of DAC. DAC represents the second 
branch point in the synthesis of β-lactam antibiotics in S. clavuligerus, dividing the 
cephalosporin C and cephamycin C pathways. To date cephamycin C has only 
been observed in bacteria.   
 
The C-3 acetoxy group of DAC is exchanged for a carbamoyl group, to form 
carbamoyldeacetylcephalosporin C. The reaction is performed by DAC-carbamoyl 
transferase, and requires carbomoyl phosphate, ATP and Mn
2+ and Mg
2+ ions 
(Brewer et al., 1980; Coque et al., 1995). The final step of cephamycin C 
biosynthesis requires the methylation of the C7 carbon of the ß-lactam ring. The 
gene products of CmcI and CmcJ are responsible for these final steps, but the 
mechanism by which these enzymes methylate their substrate is yet to be fully 
elucidated. 
 
A number of the enzymes involved in penicillin, cephalosporin C and cephamycin 
C biosynthesis have been structurally determined. The structure of IPNS from 
Aspergillus nidulans was the first to be solved (Roach et al., 1995), resulting in a 
detailed knowledge of the reaction mechanism (Burzlaff et al., 1999; Roach et al., 
1997). The structure of DAOCS from S. clavuligerus represents the first 2ODD to 
be solved (Valegård et al., 1998), and is discussed further in Chapter 3. More 
recently the structure of CmcI (Öster et al., 2006) and DAC-AT (S. Lejon, Per. 
Comm.) have been solved in the β-lactam antibiotic group in Uppsala. 
 
2.3 The Biosynthesis of Clavulanic Acid 
The total synthesis of clavulanic acid is hampered by its dense functionality and 
lability (Baggaley et al., 1997; Townsend, 2002), and therefore commercial 
production is by fermentation in submerged cultures of S. clavuligerus. As a result, 
the regulation of the genes involved in its synthesis, and characterization of the 
proteins they encode, has been studied extensively for the past 30 years. 
Approximately eighteen genes (orf2-19) appear to be responsible for the 
biosynthesis, transport, resistance to, and regulation of, clavulanic acid (Jensen et 
al., 2000; Jensen et al., 2004a; Li et al., 2000; Mellado et al., 2002), although a   30
defined function has been demonstrated for only half the genes in the cluster (see 
table 2.1). The remaining genes have a function tentatively assigned on the basis of 
sequence similarity with proteins of known function.  
 
Table 2.1 A Summary of genes and their function in the biosynthesis of clavulanic acid. 
Proteins of known function are in normal text, and in bold text if structurally determined. 
Proteins for which no specific function in clavulanic acid biosynthesis has been 
demonstrated are in italics. 
 
Gene Encodes/putative  function 
Orf2  N
2-(2-carboxyethyl)arginine synthase (CEAS2) 
Orf3  β-lactam synthase (BLS2) 
Orf4  proclavaminate amidinohydrolase (PAH2) 
Orf5  clavaminic acid synthetase (CAS2) 
Orf6  ornithine acetyltransferase (OAT2) 
Orf7  peptide binding protein 
Orf8  ClaR regulatory protein (DNA binding protein) 
Orf9  clavulanic acid dehydrogenase (CAD) 
Orf10 P450  mono-oxygenase 
Orf11 ferredoxin 
Orf12  acetyl transferase 
Orf13 efflux  pump 
Orf14 acetyltransferase 
Orf15  peptide binding protein 
Orf16 hypothetical  protein 
Orf17  N-glycyl-clavaminic acid synthetase (GCAS)  
Orf18  PBP 
Orf19  PBP 
 
Clavulanic acid and the 5S-clavams share a common biosynthetic precursor, 
clavaminic acid (Egan et al., 1997). The steps leading to the biosynthesis of 
clavaminic acid have been characterized (Figure 2.3) and the enzymes catalyzing 
them identified. In the first step L-arginine and D-glyceraldehyde-3-phosphate are 
condensed to form N
2-(2-carboxyethyl)arginine in a thiamine diphosphate-
dependent reaction, which is catalysed by the enzyme N
2-(2-carboxyethyl)arginine 
synthase (CEAS). This is followed by the formation of the β-lactam ring, by β-
lactam synthase (BLS), to yield deoxyguanidinoproclavaminic acid. The 
mechanism by which BLS forms the β-lactam ring is quite different to that in 
penicillin/cephalosporin biosynthesis. Infact BLS shows more sequence and 
structural homology to class B asparagine synthetases (Miller et al., 2001) than it 
does to IPNS. Deoxyguanidinoproclavaminic acid is subsequently converted in 
four steps to 3S,5S-clavaminic acid. Three of these steps are catalysed by the 
2ODD clavaminic acid synthase (CAS2). The first step catalysed by CAS2 
involves the hydroxylation to give a secondary alcohol (Baldwin et al., 1993), 
which is neither an inhibitor, nor a substrate of CAS2. Proclavaminate 
amidinohydrolase (PAH) hydrolyses the guanidino group to yield proclavaminic 
acid, the second substrate of CAS. In a two-step reaction CAS catalyses the 
formation of the bicyclic clavam ring, resulting in the formation of clavaminic acid.   31 
 
The crystal structures of the first four enzymes of the pathway have been reported, 
i.e. CEAS (Caines et al., 2004), BLS (Miller et al., 2001), PAH (Elkins et al., 
2002), CAS2 (Zhang et al., 2000). An additional structure, ornithine acetyl 
transferase (OAT2) has also been determined (Elkins et al., 2005). While not 
directly involved in the synthesis of clavulanic acid, this enzyme is involved in the 
biosynthesis of L-arginine from ornithine, which is required for clavulanic acid 
synthesis. It has been demonstrated that tritium-labelled ornithine is incorporated 
into clavulanate (Townsend et al., 1986). 
 
 
 
Figure 2.3 The biosynthesis of (3S,5S)-clavaminic acid from L-arginine and D-
glyceraldehyde-3-phosphate. 
 
Clavaminic acid serves as the branch point between the synthesis of the 5S-clavams 
and clavulanate (Figure 2.4). The biosynthesis of clavulanate from clavaminic acid 
requires a double epimerisation and oxidative deamination to yield (3R,5R)-
clavulanate-9-aldehyde (clavaldehyde). While this is thought to be performed by 
the gene products of orf10 and orf11, there is little mechanistic information on how 
this is achieved at present. Recently it was shown that orf17 encodes a N-glycyl-
clavaminic acid synthetase (Arulanantham et al., 2006), capable of converting 
clavaminic acid to N-glycyl-clavaminic acid in an ATP dependent reaction. 
Whether N-glycyl-clavaminic acid represents an additional step in the synthesis of 
clavulanic acid remains unclear at present. The final step in clavulanic acid 
biosynthesis results in the reduction of clavulanate-9-aldehyde (clavaldehyde) 
catalysed by clavulanic acid dehydrogenase (CAD) (Fulston et al., 2001; 
Nicholson et al., 1994)). The structure of CAD, and the reaction catalysed by it are 
discussed in further detail in Chapter 4. 
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Figure 2.4 Potential biosynthetic pathway from (3S,5S)-clavaminic acid to both the 5S-
clavams and (3R,5R)-clavulanic acid (Baldwin et al., 1994; Liras & Rodriguez-Garcia, 
2000). Proposed intermediates are in boxes. The N-acetyl derivatives of clavaminic acid 
accumulating in the dcl8 mutant of S. clavuligerus (Elson et al., 1998) are shown in Box A. 
 
Recently, the gene products of orf18 and orf19 where shown to encode the high 
molecular weight membrane bound PBPs PbpA and Pbp2, respectively (Ishida et 
al., 2006). Both PBPs showed a reduced affinity for β-lactam antibiotics and 
clavulanic acid, where Pbp2 possessed the lowest affinity for clavulanic acid 
between the two PBPs. The synthesis of PBPs resistant to β-lactam antibiotics and 
clavulanic acid affords a means by which S. clavuligerus is able to achieve self-
resistance. 
 
The exact role of the remaining nine ORFs (orf12–16, orf7) in clavulanic acid 
biosynthesis remains unclear at present. Knockout disruption-mutant studies 
suggested that orf7, orf10, orf12, orf15, orf16 and orf17 were essential for the 
synthesis of clavulanic acid. Mutants of orf11, and orf13 were severely 
compromised, but did produce detectable levels of products (Jensen et al., 2004a). 
The reported effects of disrupting orf14 vary from partial loss (Mellado et al., 
2002) to almost complete loss of clavulanic acid production (Jensen et al., 2004a).   
 
The disruption mutations also had an effect on the production of 5S-clavams, 
among these 2-hydroxymethylclavam, clavam-2-carboxylate and alanylclavam. 
The production of 5S-clavams are typically more variable, even in wild-type strains   33 
(Thai et al., 2001), however the disruption of orf11 and orf13 resulted in a 50-90% 
and 90-100% reduction of C-2-C and 2HMC, respectively. The levels of 5S-
clavams in the other mutants varied, although detectable levels were produced 
(Jensen et al., 2004a). In addition the knockout-disruption of orf15 or orf16 
resulted in the production of N-acetyl-glycyl-clavaminic acid (NAG-clavam) and 
N-glycyl-clavaminic acid, two 5S-clavam previously detected in the dcl8 mutant 
(Elson et al., 1998). 
 
The role of the remaining ORFs is further complicated by the observation that the 
gene disruption of several ORFs (or10, orf12, and orf15) resulted in the synthesis 
of the non-β-lactam antibiotic holomycin (de la Fuente et al., 2002; Lorenzana et 
al., 2004). 
 
2.4 Aims of the Thesis 
In order to further study the enzymes involved in β-lactam antibiotic production we 
have used a structural approach, through the technique of X-ray crystallography. 
The shape of a protein determines, in part, its function. Thus an understanding of 
the three-dimensional structure of a protein can lead to detailed knowledge at the 
molecular level of how a particular protein performs its role. 
 
The genes involved in the biosynthesis of penicillin N, cephalosporin C, and 
cephamycin C have been identified and characterised. However, the mechanisms 
by which many of the enzymes catalyse their reactions remains to be determined. 
For example, several of the genes involved encode non-heme iron oxygenases e.g. 
IPNS; DAOCS, DACS, and DAOC/DAC, most of which are 2ODDs. These 
enzymes are thought to perform catalysis using a highly oxidising iron(IV) species, 
however this ferryl intermediate has only been observed via spectroscopic methods 
(Proshlyakov et al., 2004). 
 
The number of genes known to be involved in the biosynthesis of clavulanic acid 
has increased dramatically in the last few years, initially six ORFs, then nine ORFs, 
and now eighteen ORFs. Approximately half of the functional assignments are 
based on sequence similarity to other proteins rather than a known function. The 
aim of this thesis is to further examine the mechanism of action of enzymes and 
proteins involved in the synthesis of β-lactam antibiotics in S. clavuligerus. 
 
The story of penicillin provides a wonderful example of how basic research lead to 
the serendipitous discovery of a compound that ultimately changed human history. 
However, the subsequent research and development of penicillin represented a 
concerted scientific effort to understand not only how penicillin works, but how it 
could be improved. The research contained within this thesis does not contain 
serendipitous discoveries that will be as herald as penicillin. However, this thesis 
contributes to the research and knowledge required to understand how β-lactam 
compounds are synthesised in natures ”chemical kitchen”. Ultimately this boils 
down to a simple desideratum; new β-lactam antibiotics with which to fight our 
battle against pathogenic bacteria. Through a greater understanding of the 
underlying processes we can improve the yields using the existing techniques, and   34
hopefully in the future identify more environmentally friendly and inexpensive 
synthetic routes to new more powerful antibiotics.   35 
3 Deacetoxycephalosporin C Synthase, DAOCS 
(Paper I) 
3.1 Background 
The gene CefE in the cephamycin gene cluster of S. clavuligerus encodes for the 
enzyme deacetoxycephalosporin C synthase (DAOCS). DAOCS is responsible for 
the expansion of the five-membered thiazolidine ring of penicillin N to the six-
membered dihydrothiazine ring of deacetoxycephalosporin (DAOC), illustrated in 
figure 3.1. DAOCS is also capable of expanding the thiazolidine ring of various 
other penicillins, albeit with a reduced efficiency (Lloyd et al., 1999). 
 
 
 
Figure 3.1 The ring expansion reaction catalysed by DAOCS. 
 
The enzyme belongs to a class of enzymes known as 2-oxoglutarate dependent 
dioxygenases (2ODDs), which require a non-heme iron, 2-oxoglutarate and 
dioxygen (Prescott, 1993).  DAOCS was the first 2ODD structure to be determined 
(Valegård et al., 1998), and was found to possess a fold similar to that of IPNS 
(Roach et al., 1995). The structure of DAOCS consisted of a distorted jelly roll 
fold, flanked by α-helices, where Fe(II) is coordinated by two histidines and an 
aspartic acid. Since then several other 2ODD structures have been determined, e.g. 
CAS (Zhang et al., 2000), CAR-C (Clifton et al., 2003), ACCO (Zhang et al., 
2004), proline-3-hydroxylase (Clifton et al., 2001).  Despite low sequence 
similarity within the 2ODD family, their structures reveal a common fold, i.e. the 
distorted jelly roll. The 2ODD structures also reveal the similar nature of Fe(II) 
coordination, where two histidines and one aspartic acid or glutamic acid create the 
2-His-carboxylate facial triad motif (Hegg & Que, 1997). 
 
In order to bind/react with oxygen, Fe(II) must first be activated. 2-Oxoglutarate 
binds to the iron and activates it for the binding of oxygen. In the process of this 
activation 2-oxoglutarate is decarboxylated to succinate, generating CO2 and an 
oxidising intermediate, i.e. a ferryl-species Fe(IV). Succinate is ligated to the iron, 
and most probably serves to stabilise the reative intermediate prior to the binding 
of penicillin. In order for penicillin to bind, succinate must first be expelled from
the active site. This triggers oxidative attack on penicillin, ultimately leading to
the expansion of the penam ring, resulting in the formation of cephalosporin and 
water in the active site. The high resolution structure of DAOCS led to the   36
proposal of a mechanism for the formation of the ferryl intermediate (Valegård et 
al., 1998), however the later catalytic steps, resulting in the formation of the 
cephalosporin, are yet to be fully elucidated. These latter steps are of particular 
interest since the identification of the residues involved in binding and catalysis 
would be invaluable for future genetic redesigning of DAOCS. 
 
Further insight into the catalytic reaction performed by DAOCS could be gleaned 
by the capture of the ferryl-intermediate using protein crystallography. The ferryl-
intermediate is most likely reduced by the X-ray beam during data collection, 
preventing it from being seen in the crystal structure. By using the techniques of 
time resolved crystallography, in a manner similar to that used by Berglund et al., 
(2002), it could be possible to capture the ferryl intermediate in short time slices, 
before the high oxidation state is reduced.. This would hopefully lead to an 
enhanced understanding of the reaction mechanism.  
 
3.2 An Alternate Crystal Packing of DAOCS is Required 
The crystallization of native DAOCS protein resulted in the formation of crystals 
belonging to the space group R3 (Valegård et al., 1998). Structure determination 
using the R3 crystals was, however, hampered by merohedral twinning (Terwisscha 
van Scheltinga et al., 2001). Merohedral twinning is a packing anomaly, where 
distinct domains of the protein can pack in alternate orientations within the three 
dimensions of the crystal. The degree of twinning can range from no twinning 
(twin fraction 0) to almost perfect twinning (twin fraction 0.5). The twin fraction of 
the data can be estimated, allowing the data to be “detwinned”. However, such 
methods amplify experimental errors, where the experimental error introduced by 
detwinning is proportional to the twin fraction. To capture the DAOCS ferryl-
intermediate using protein crystallography would require the collection of data on 
crystals with a twin fraction of less than 0.3. 
 
The structure of the apo enzyme revealed that the monomers are arranged in a 
trimer (Figure 3.2), where the carboxyl-terminal arm (residues 308-311) binds in 
the active site of a neighbouring molecule. If the packing of DAOCS within the 
crystal could be significantly altered, it may be possible to overcome the technical 
difficulties associated with merohedral twinning. Crystallization conditions had 
been extensively screened for conditions conducive to an alternate crystal form, 
however none were identified. Thus, modifications to the enzyme preventing the 
formation of the R3 trimer were required.  This could be achieved by the deletion 
of the C-terminal arm, since it is involved in trimer formation. However the C-
terminal arm is important for enzymatic activity, as demonstrated by mutation and 
truncation studies (Chin & Sim, 2002; Lee et al., 2001; Lee et al., 2002). Instead, 
DAOCS was expressed with an N-terminal His(6)-tag, where the resulting fusion 
protein produced crystals belonging to an alternate space group.   37 
 
3.3 Sub-cloning, and Initial Expression and Purification Trials 
The daocs/cefE gene from S. clavuligerus was amplified by PCR from the pML1 
plasmid (Lloyd et al., 1999) using the PCR primers: forward primer 5’ – CAT 
GGC AGC CAT ATG GAC ACG ACG GTG CCC ACC TTC AG – 3’ ; reverse 
primer 5’–AGC AGC CGG ATC CTC CTA TGC CTT GGA TGT GCG GCG 
GAT G – 3’.  The PCR product was cloned into the pET15b expression vector 
using the Nde I and BamH I restriction sites. Positive clones of the daocs/pET15b 
construct were selected on LB-agar plates using ampicillin (100 µg ml-1) as a 
selection marker, and confirmed with restriction enzyme digests and directional 
PCR. The daocs/pET15b construct was then transformed into E. coli BL21 (DE3) 
cells. Initial expression trials were conducted at 30 °C and 37 °C using 100 ml E. 
coli cultures grown in LB medium containing ampicillin. Recombinant protein 
expression was induced with 0.5 mM IPTG at an OD600nm = 1.00. The reduction of 
growth temperature to 30 °C resulted in increased expression of soluble 
recombinant protein (data not shown). 
 
The pET15 expression vector contained an N-terminal poly His(6)-tag and a 
thrombin protease site, thus the protein could be separated from the lysed bacterial 
culture using immobilised-metal-affinity-chromatography (IMAC). The initial 
purification trial used a 1 L culture of E. coli grown at 30° C. Protein expression 
was induced as described above, and cells harvested 2 hours after induction by 
centrifugation at 5,000 g for 15 minutes at 4 °C. The bacterial pellet was 
resuspended in lysis buffer consisting of 50 mM NaH2PO4 (pH 8.0), 500 mM 
NaCl, and 10 mM imidazole. Total cells were disrupted by sonication and the 
lysate cleared by centrifugation at 12,000 g for 30 minutes at 4 °C. The cleared 
lysate was loaded onto a Ni-NTA column and subsequently eluted using a 
imadazole gradient of 10–300 mM imidazole. Fractions containing protein were 
analysed by SDS-PAGE, with appropriate fractions pooled and concentrated. The 
concentrated protein was subjected to size exclusion chromatography using a 
Superdex75 gel filtration column, before being concentrated once again. The 
resulting protein was deemed very pure (>95%) as judged by SDS. 
 
The purification of the His(6)-DAOC protein was more rapid in comparison to the 
procedures for the native protein (Lloyd et al., 1999). This is important when 
considering that mononuclear ferrous enzymes are sensitive to oxygen, degrading 
under aerobic conditions (Barlow et al., 1997). 
 
3.4 A Summary of Subsequent Results 
(The subsequent purification, crystallization, and structural determination of the 
His(6)-DAOCS protein was performed by L. Öster (Paper I). The effect of the 
His(6)-tag on crystallization, and crystal packing will be discussed here. The results 
from the complexes of DAOCS-Fe(II)-2-oxoglutarate,  DAOCS-Fe(II)-succinate, 
DAOCS-Fe(II)-ampicillin, and DAOCS-Fe(II)-2-cephalosporin C will not.)   38
 
3.4.1 Effect of His(6)-Tag on Crystallization 
The His-tagged DAOCS crystals were obtained in conditions similar to the native 
protein, except that the concentration of ammonium sulphate was reduced from 
1.75 M to 0.9–1.1 M and the pH was reduced from 7.0–7.5 to 8.0. The optimum 
temperature for crystallization was dramatically altered from 20 °C for the native 
protein, to 4 °C for the His-tagged protein. Furthermore, the addition of 2-
oxoglutarate was no longer required to obtain crystals of the new His-tagged 
protein. Previously the technique of seeding was essential to obtaining native 
crystals, however crystals of the His-tagged protein grew spontaneously. In fact, it 
was necessary to slow the rate of vapour diffusion using Al’s oils (Hampton), 
reducing the formation of microcrystals. 
 
3.4.2 Effect of His(6)-Tag on Crystal Packing 
The resulting crystals of His-tagged protein were hexagonal rods, belonging to the 
space group P3121, which differs to the previous rhombohedrally shaped crystals 
belonging to space group R3. Most importantly the new (His-tagged) crystals did 
not show merohedral twinning. This is due to a considerable difference in the 
packing of molecules within the crystal (see Figure 3.2). Although the molecules of 
DAOCS are still arranged as trimers in the new crystal form, the symmetry of the 
P3121 trimer is quite different to that of the R3 trimer. This difference is most 
likely due to disruption of the N-terminal interaction between adjacent molecules 
seen in the R3 trimer. As a result of the new trimer symmetry the C-terminal arm 
no longer binds within the active site. Thus the N- and C-terminal residues are no 
longer involved in any intermolecular contacts in the new crystal form. 
 
Unfortunately the packing of molecules within the new crystal form created large 
solvent channels, increasing the solvent content of the crystals to ca. 70%, much 
higher than the previous ca. 40% (R3 crystals). This resulted in fragile, and 
difficult to handle, crystals. Such a high solvent content would also allow for 
increased flexibility in the crystal lattice, where this may partially account for the 
poorer diffraction quality of the new crystals (2.3 Å compared to 1.3 Å). 
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Figure 3.2 Packing of molecules within the two different crystal forms. In both cases 
DAOCS forms trimers, although the interactions forming these trimers are mediated by 
different regions of the protein. (A) The R3 crystal form as viewed down the three-fold 
symmetry axis, note the dense packing of molecules contributing to a low solvent content. 
(B) The P3121 crystal form, viewed down the three-fold axis, note the large solvent 
channels formed between the trimers.   40
4 Clavulanic Acid Dehydrogenase, CAD (Paper 
II) 
4.1 Background 
The clavam 3R,5R-clavulanate-9-aldehyde (clavaldehyde) is a potent inhibitor of 
β-lactamases, unfortunately the electron drawing properties of the α/β-unsaturated 
allylic aldehyde make it an unstable molecule. It is susceptible to hydrolysis in 
solution, with a half-life of approximately one hour (Fulston et al., 2001; 
Nicholson et al., 1994), resulting in fragmentation of the bicyclic ring (Baggaley et 
al., 1997). The reduction of the C9-aldehyde to an alcohol increases the stability of 
the β-lactamase inhibitor in solution, and thus clavaldehyde represents the final 
intermediate in the biosynthesis of clavulanic acid.   
 
The penultimate step (Figure 4.1) is catalyzed by clavulanic acid dehydrogenase 
(CAD), also known as clavulanate-9-aldehyde reductase (CAR) (Perez-Redondo et 
al., 1998). The reaction catalyzed by CAD is dependent upon the nucleotide co-
factor NADPH (Nicholson et al., 1994, Fulston et al., 2001).  
 
 
 
 
Figure 4.1 The CAD catalysed reduction of clavulanate-9-aldehyde to clavulanic acid using 
the cofactor NADPH. 
 
The enzyme CAD is encoded by orf9 in the clavam gene cluster, and is expressed 
as a monosistronic transcript (Perez-Redondo et al., 1998), under the regulation of 
the ClaR promoter. To date no homolog has been observed elsewhere in the 
genome. Sequence analysis of CAD reveals similarity to the Short Chain 
Dehydrogenase/Reductase (SDR) family (Nicholson et al., 1994). Over 3000 SDR 
members have been identified, with diverse substrates, ranging from alcohols and 
sugars to steroids and aromatic compounds. SDRs are formed by subunits of 
approximately 250 amino acids. The sequence identity within the SDR family is 
typically low, in the order of 15-30%. There are very few highly conserved 
residues characterizing the family, although a number of important motifs can be 
identified. Despite the low identity within the family, the SDRs show a conserved 
structural motif (β/α/β), i.e. the Rossmann fold, which is common for enzymes 
binding nucleotide coenzymes (Rossmann et al., 1975). 
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An important question in clavulanic acid biosynthesis is how the highly labile 
intermediates are efficiently processed through the pathway. Of particular interest 
is how CAD can catalyses the reduction of the unstable clavaldehyde without 
fragmentation of the bicyclic ring. In order to further investigate the nature of the 
CAD catalysed reaction, the structure of CAD was determined, along with CAD in 
complex with clavulanic acid. 
 
4.2 Expression, Purification, and Crystallization of CAD 
4.2.1 Initial Trials Using Recombinant Fusion Protein 
Cad/orf9 was amplified by PCR from a genomic DNA preparation from S. 
clavuligerus (courtesy of M. Svenda) and cloned into a pET30 (N-terminal His(6)-
Tag) and pET32 (Trx-His(6)-Tag) vector, using ligation independent cloning 
(Novagen). The cad/pET constructs were transformed into E. coli pLysS (DE3), 
and grown in LB medium at 18 °C using appropriate selection markers. 
Recombinant protein expression was induced at a cell density of OD600 = 0.5, by 
the addition of 0.5 mM isopropyl IPTG, and the temperature raised to 27 °C. Cells 
were harvested by centrifugation five to six hours after induction, and stored at –80 
°C.   
 
The recombinant protein was purified using a combination of affinity 
chromatography (Ni-NTA), anion exchange chromatography (mono-Q) and size 
exclusion chromatography (Sephadex 200) all at pH 8.0. Fractions were checked 
for purity using SDS-PAGE. Purified protein from the cad/His(6) construct was 
light brown in colour, precipitated readily upon concentration, and was partially 
truncated when visualized on SDS-PAGE (ca. 26 kDa.). No further work continued 
using this construct. The cad/Trx-His(6) construct (ca. 54 kDa.) resulted in the 
production of considerable quantities of super soluble protein, ca. 80 – 100 mg ml
-
1. Despite numerous crystallization trials, conditions suitable to crystallization 
could not be identified. Removal of the thioredoxin/His6 tag using the protease 
Factor Xa resulted in the production of native CAD, which when concentrated (ca. 
10 mg ml-1), resulted in the formation of crystals overnight (Crystal screen I, 
Hampton Ltd). The crystals appeared as small overlapping needles, fused together, 
and could not be successfully separated. The resulting diffraction pattern could not 
be processed, due to very high mosaicity and split reflections. 
 
4.2.2 Initial Trials Using Native Protein 
In order to avoid cleavage of the Trx/His6 fusion protein further work continued 
using the native cad/pET24(+) (cad/Native) construct obtained from Oxford 
(courtesy of N. Kershaw, Oxford). The construct was transformed into E. coli 
BL21 (DE3) and the cells grown in LB media as previously described.  The initial 
purification protocol consisted of anion and cation exchange chromatography, 
using mono-Q (Tris-HCl pH 8.0) and mono-S (MES pH 5.5).  The changing of pH 
by dialysis resulted in partial precipitation of CAD (pI 6.5), although significant 
quantities of protein remained soluble, allowing continued purification using gel 
filtration (Tris-HCl pH 8.0).  The purified protein was over 95% pure, as judged by 
SDS-PAGE and was concentrated to ca. 10 mg ml
-1.   42
 
Small crystals were obtained using Clear Screen I (Molecular Dimensions) with 
cacodylate (pH 6.5) as the buffering agent. The inclusion of 2 mM NADPH 
improved the visual appearance of the crystals, and seeding improved crystal size. 
A needle-shaped crystal was prized apart, and frozen in liquid nitrogen using 
glycerol as a cryo-protectant. A complete data set to 1.8 Å was collected on a 
crystal at the ESRF (Grenoble, France). The crystals belonged to space group P21, 
with unit cell dimensions of a = 91.8 Å, b = 87.5 Å, c = 91.9 Å, b = 119°. The 
Matthews coefficient indicated an estimated four, or six, molecules in the 
asymmetric unit. Despite extensive attempts, the structure could not be solved 
using molecular replacement. An alternate protocol devised by colleagues in 
Oxford resulted in the formation of crystals belonging to an orthorhombic space 
group. Crystals obtained from either of the two purification protocols were 
unsuitable for phase determination by the method of Multiple Isomorphous 
Replacement (MIR) due to a lack of isomorphism between the crystals.  
 
4.2.3  Expression, Purification, and Crystallization of SeMet Protein 
The  cad/Native construct was transformed into E. coli 834 (DE3). Cells were 
grown in SeMet medium, using L-seleno-methionine (Molecular Dimensions), and 
the same temperature regime and procedures as previously described. The 
recombinant protein was purified as described above, except that 5 mM β-
mercaptoethanol was added to all the solutions. It is interesting to note that the 
SeMet-labelled CAD did not bind to the Mono-Q column, possibly as a result of an 
altered isoelectric point due to SeMet incorporation. Instead, an equal volume of 
2M (NH4)2SO4 was added to the flow-through, and purification continued as usual. 
The purified protein was concentrated (ca. 8 mg ml
-1) and stored in 5 mM HEPES 
(pH 7.5), 1 mM EDTA and 5 mM β-mercaptoethanol.   
 
Previous CAD crystals had been obtained using cacodylate (pH 6.5) as a buffering 
agent. However, cacodylate contains arsenic, which gives an anomalous signal 
close to the selenium absorption edge, thus to reduce potential problems with data 
collection the crystallization buffer was changed to Bis-Tris (pH 6.5). Small 
crystals were obtained using equal volumes of a reservoir solution consisting of 10 
% (w/v) PEG 1000, 10 % (w/v) PEG 8000, and 0.3 M sodium acetate, and protein 
(ca. 6 mg ml
-1). The small crystals were crushed, and used for streak seeding into a 
drop consisting of 2 µl of protein (ca. 3 mg ml
-1 + 2 mM NADPH) and 2 µl of the 
same reservoir solution. This resulted in the growth of crystals within 1 to 3 days at 
22 °C. The crystals were prepared for data collection at cryogenic temperatures by 
transfer to a cryo-solution consisting of the reservoir solution containing 25% PEG 
400, followed by submersion in liquid nitrogen.   43 
4.3 Structure Determination and Model Building 
4.3.1 Location of the Selenium Atom Sites 
A single-wavelength anomalous diffraction (SAD) data set was collected on a 
SeMet crystal at a fixed wavelength beam line ID14-3 (ESRF, Grenoble, France).  
The crystal diffracted to 1.8 Å, and belonged to an orthorhombic space group 
(P222), with cell dimensions a = 58 Å, b = 122 Å, c = 126 Å.  The dimensions of 
the a-axis were initially misinterpreted as being 116 Å, due to the presence of a 
‘ghost’ diffraction pattern.  The space group could not be confidently assigned, as 
the intensities along the h axis were incomplete, i.e. the k + l = 0 systematic 
absences had not been measured. The data were initially processed to 1.9Å (360°) 
using DENZO and SCALEPACK (Otwinowski & Minor, 1997) in the space 
groups  P21212 due to isomorphism with a previous Pt cyanide MAD data set.   
Assuming the presence of four molecules in the asymmetric unit gave a VM of 2.2 
Å
3 Da
-1 (Matthews, 1968) with 42.7% solvent. The protein sequence for CAD 
predicted seven methionines, although ESI mass spectrometry and Edman 
sequencing confirmed the loss of the N-terminal methionine (Paper II). The 
SHELX suit (Schneider & Sheldrick, 2002) was used to locate the 24 selenium 
sites.  Initial SHELX trials indicated sufficient anomalous signal, but the 20 heavy 
atom sites located were of dubious quality, due to low occupancy. The 
reprocessing of the data in the space group P212121, and the re-running of SHELX 
using the options “NO PATS” and “WEED” resulted in improved heavy atom site 
occupancies, with a clear difference in hand after solvent flattening.  However, a 
model could not be built into the electron density. Attempts to identify the non-
crystallographic symmetry (NCS) arrangement of the selenium sites in O (Jones et 
al., 1991), revealed the presence of an almost pure translation vector, confirmed by 
FFT (CCP4, 1994). This accounted for the improvement of heavy atom sites using 
the “NO PATS” option in SHELX. The refinement of the heavy atom sites using 
Auto-Sharp (La Fortelle & Bricogne, 1997) resulted in the identification of three 
more selenium sites, and solvent flattening with SOLOMON (Abrahams & Leslie, 
1996) showed a clear distinction between the solvent and the four molecules of the 
asymmetric unit. The running of Auto-Sharp using “auto-build” (ARP-wARP 
(Perrakis et al., 1999)) resulted in the building of several β-strands, arranged in 
manner similar to a related SDR, Rv2002 from Mycobacterium tuberculosis (pdb 
code 1NFF) (Yang et al., 2003). 
 
4.3.2 Model Building 
The monomer of the related SDR from Mycobacterium was used as a search model 
to locate the four molecules in the electron density maps from Auto-Sharp using 
MolRep (Vagin & Teplyakov, 1997). Rigid body refinement of the phased 
molecular replacement solution showed the clear presence of the co-substrate, 
NADPH, in the electron density. A poly-alanine model was prepared, and further 
building continued using ARP-wARP. A mask was prepared using MAMA and the 
NCS symmetry operators determined in O (Jones et al., 1991), allowing electron 
density averaging using the RAVE suite of programs (Kleywegt & Jones, 1999; 
Kleywegt & Read, 1997). The averaged maps, in combination with the heavy atom 
sites, allowed manual docking of the sequence to the partial model. Further   44
building cycled between ARP-wARP and RAVE, with manual rebuilding of the 
model using O. This resulted in a complete model from Ser
3 to Val
247, where 
additional electron density for Pro
2 could be seen in one of the molecules. No 
electron density was observed for the Met
1, consistent with the EPI-MS and Edman 
sequencing data. 
 
4.3.3 Model Refinement 
The data were re-processed  to 1.8 Å using MOSFLM (CCP4, 1994; Leslie, 1992) 
and SCALA (CCP4, 1994), using the first 137 ° of rotation, thus omitting data 
most severely affected by radiation damage during collection. The model was 
initially refined in CNS (Brunger et al., 1998) using simulated annealing with 4-
fold NCS constraints, and unbiased HL coefficients from auto-SHARP. The co-
factor could be clearly seen in both the 2Fo and Fo-Fc maps (contoured at 1.0 δ, and 
4.0 δ, respectively), and was subsequently modelled as NADPH, even though the 
puckering of the reduced nicotinamide ring could not be seen at 1.8 Å resolution. 
Refinement continued using CNS with gradual relaxation of the NCS parameters, 
from four-fold constraints, to two-fold constraints, and finally to four-fold 
restraints. The final stages of refinement were performed using REFMAC5 
(Murshudov et al., 1997) where TLS refinement (Winn et al., 2001) with each 
monomer as a TLS group resulted in a significant drop in both Rcryst and Rfree. 
Solvent molecules were added using ARP-wARP (Lamzin et al., 2001) and were 
manually inspected in O. The final model has an Rcryst of 18.2 % and an Rfree of 
20.9%. 
 
4.4 Structure of CAD 
4.4.1 Secondary and Tertiary Structure 
Previous sequence analysis of CAD revealed homology to enzymes belonging to 
the SDR family (Nicholson et al., 1994). Members of the SDR family possess very 
few highly conserved residues, and generally show low sequence homology, in the 
order of 15-30%. The three-dimensional structures of SDRs show a conserved 
Rossmann fold, common to nucleotide-binding enzymes (Rossmann et al., 1974). 
The structure of CAD reveals that the enzyme consists of a single α/β domain, 
composed of seven β-strands (βA, βB, βC, βD, βE, βF, βG) and eight α-helices 
(αB,  αC, αD, αE, αF, αFG1, αFG2, αG), consistent with the Rossmann fold. 
Seven β-strands form a parallel β-sheet, which is flanked by helices αC, αB, and 
αG on one side, and helices αD, αE, and αF on the other. Helices αFG1 and αFG2 
are positioned to one side over the top edge of the C-terminal end of the β-sheet, 
the co-factor binding site. Helix αFG1 lies in a similar plane to helix αB, except 
that the helical axis is pointing towards the pyrophosphate moiety of the nucleotide 
cofactor, in a manner similar to helix αB.  Helix αFG2 lies on the top edge of the 
β-sheet, and assists in the creation of the substrate-binding site. 
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Figure 4.2 The Rossmann fold of CAD. (A) The tertiary structure of CAD, where the N-
terminus and α-helices are labelled. (B) Tertiary structure of CAD as viewed perpendicular 
to the parallel β-sheet, where the C-terminus and β-strands are labelled. (C) The secondary 
structure elements and their topological relationship to each other. 
 
4.4.2 Quaternary Structure 
The four molecules (A–D) of the asymmetric unit are arranged to form a tetramer, 
possessing 222 point symmetry (Figure 4.3). The arrangement is similar to that 
observed in other tetrameric SDRs. This results in the formation of three two-fold 
axes, which have been labelled P, Q, and R (after Rossmann et al., 1973). These 
axes represent the interfaces of the tetramer interactions. The interactions along the 
P and Q axes comprise the greatest interaction surface area, with 1390 Å
2 and 1631 
Å
2 per monomer, respectively. The R axis contributes little to tetramer formation, 
with 80 Å
2 per monomer. The interactions of the P axis consist of the hydrophobic 
interactions of helix αG between monomers A and B, and by the hydrogen bonding   46
of β-sheet extension (βG). The Q interface is characterized by the hydrophobic 
interaction of two helices, αE and αF, from both the A and C monomers, which 
results in the formation of a four-helix bundle.  
 
The interactions along the P and Q axes are important for defining the oligomeric 
state of SDRs. For example the rat liver dihydropteridine reductase contains an 
eighth parallel β-strand, preventing tetramer interactions along the P axis 
(Varughese et al., 1992). Alternatively, the 3α-hydroxysteroid 
dehydrogenase/carbonyl reductase possesses two additional α-helices prior to αF, 
which prevent dimer interactions along the Q axis, preventing the formation of the 
four-helix bundle (Grimm et al., 2000). Dimer interactions along the Q axis are 
favoured, due to a reduction in the hydrophobic surface exposed to the solvent 
(Sawicki et al., 1999), thus the dimeric form of CAD observed in solution most 
likely consists of this Q-axis dimer (molecules A and C). 
 
 
 
Figure 4.3 Quaternary structure of CAD. The P, Q, and R axes are indicated, where the R 
axis is parallel to the point of view. The A|B dimer (light grey) forms the P axis, and the 
A|C dimer (light grey| dark grey) forms the Q axis. 
 
In comparison to many other tetrameric SDRs CAD shows reduced interactions 
along the R axis, due to a shorter C-terminal tail, which is held in a more compact 
position. The C-terminal tail is tucked in close to αFG2, where this interaction is 
aided by a salt bridge between Arg
213 and Asp
245. The hydrogen bonding   47 
interactions between Gln
246 and Thr
187 may also contribute, although these residues 
are also involved in the binding of the substrate.  
 
In between the four CAD monomers a tunnel is formed, running along the R-axis, 
with approximate dimensions of 8 Å x 13 Å x 34 Å (Figure 4.4). The tunnel is 
filled with solvent, allowing for hydrogen bonding interactions between all four 
monomers  via extended solvent bridges. Similar tunnels can be found in other 
tetrameric SDRs, although the C-terminal tail frequently forms a cap over the 
tunnel, closing it to the external solvent. In CAD, the substrate binding sites from 
two monomers related by the R-axis (e.g. monomers B and C) are located in close 
proximity to the tunnel entrance. The tunnel is of sufficient size to permit 
movement of the substrate through the tunnel, although this is unlikely to happen in 
a solvent filled tunnel. 
 
 
 
Figure 4.4 A surface projection showing the tunnel formed between the four monomers of 
the tetramer, as viewed along the R axis. The position of the substrate binding sites are 
shown in black. 
 
4.5 Similarity with Other SDRs 
4.5.1 Sequence Similarity 
The SDR superfamily can be classified into five different families based on 
conserved sequence motifs (Kallberg et al., 2002). Few residues are strictly 
conserved throughout the superfamily, not even the residues of the catalytic triad 
(S, Y, K), which define reductase activity (Jornvall et al., 1995). For example, in 
human mitochondrial 2,4-dienoyl-coA reductase the typical YxxxK motif is 
replaced by the unique YxxxN motif (Alphey et al., 2005), while in the enol-ACP 
reductase from Mycobacterium tuberculosis the conserved tyrosine is substituted 
for methionine, YxxMxxxK (Rozwarski et al., 1999).    48
 
Several of the motifs defining classical SDRs are present in CAD. The Asn
90-
Asn
91-Ala
92-Gly
93 motif is important in stabilizing the central β-sheet (Filling et al., 
2002), while the glycine rich motif, Thr
13-Gly
14-X3-Gly
18-X-Gly
20, assists the 
binding of the dinucleotide cofactor (Jornvall et al., 1995). Asp
64 has been 
proposed to assist stabilization of a pocket binding the cofactor adenine ring 
(Filling et al., 2002), however in CAD it appears to also interact directly with the 
adenine ring. The catalytic triad has been extended to include a conserved 
asparagine and water molecule, giving rise to the catalytic tetrad (Filling et al., 
2002; Oppermann et al., 2003). Both the catalytic triad (Ser
142, Tyr
155, and Lys
159) 
and Asn
115 are conserved in CAD, as is the water molecule associated with Asn
115 
(see Section 4.7.) Another conserved water molecule found linking the glycine rich 
nucleotide binding motif, the cofactor pyrophosphate, and the C-terminal residue 
of βD (i.e. Asn
91) in other SDRs (Bottoms et al., 2002) is also conserved in CAD.  
  
Members of the classical SDR family can be classified further based on their 
cofactor dependence (Kallberg et al., 2002). The fact that CAD is dependent on 
NADPH as a cofactor, rather than NADH (Fulston et al., 2001) Paper II) is 
consistent with its structure. Classical SDRs binding NAD(H) possess an acidic 
residue at the end of strand βB, which interacts with the adenosine-ribose hydroxyl 
groups,  e.g. Asp
38 in the 3α,20β-hydroxysteroid dehydrogenase (Ghosh et al., 
1994). In CAD this position is occupied by the non-polar residue, Ala
38, preventing 
any electrostatic repulsion of the negatively charged 2’-phosphate group of the 
cofactor. Classical SDR enzymes binding NADP(H) generally possess two 
characteristic basic residues: the first immediately preceding the second glycine of 
the glycine-rich cofactor-binding motif, and the second following directly after the 
crucial acidic residue of NAD(H)-preferring enzymes (Kallberg et al., 2002; 
Tanaka et al., 2001). In CAD these positions correspond to residues Ser
17 and 
Arg
39, both of which coordinate phosphate oxygen’s from the pyrophosphate, and 
adenine-phosphate respectively. The substitution of Ser
17 for a basic residue 
demonstrates that the requirement for basic residues is not absolute, and thus CAD 
can be classified into the cP2 subfamily (Kallberg et al., 2002). 
 
4.5.2 Structural Similarity 
A Cα alignment of SDRs reveals the conserved nature of the α/β fold (Figure 4.5), 
where significant variation can be found between the structures around the C-
terminus, and around helices αFG1 and αFG2. The variation in the C-terminal 
region is important for interactions along the P and R interfaces (Figure 4.5f). The 
variation found in the αFG1–αFG2 region is due to its proximity to the binding 
site, where these helices form a lid over the substrate-binding site (Duax et al., 
1996; Tanaka et al., 2001). Given the diverse range of substrate specificities of 
SDR enzymes, the variation in this region is hardly surprising. Since the substrate 
of CAD is a relatively small molecule, the αFG1–αFG2 lid adopt a rather closed 
conformation in comparison to other SDRs. The closed conformation of the lid 
region is stabilised by the interactions between the αFG1-αFG2 loop and the βE-
αE loop, where hydrogen bonds between Thr
197 and Asp
107 and the carbonyl group   49 
of Leu
97 link the two loops via a solvent bridge (e.g. water Z
61 in the binary 
complex).  
 
 
 
Figure 4.5 (A) – (F) Legend on next page.   50
Figure 4.5 Conservation of the Rossmann-fold in CAD (grey) and other SDR enzymes 
(black). The Cα alignment of CAD (2JAH) with (A) 3α,20β-hydroxysteroid dehydrogenase 
(2HSD, r.m.s.d. = 1.21 Å for 207 atoms). (B) β-keto acyl carrier protein reductase (1EDO, 
r.m.s.d. = 1.26 Å for 217 atoms). (C) meso-2,3-butanediol dehydrogenase (1GEG, r.m.s.d. = 
1.24 Å for 215 atoms). (D) Rv2002 (1NFF, r.m.s.d. = 1.31 Å for 212 atoms). (E) 3β/17β 
hydroxysteroid dehydrogenase (1HXH, r.m.s.d. 1.23 Å for 206 atoms. (F) Rat liver 
dihydropteridine reductase (1DHR, r.m.s.d. = 1.88 Å for 166 atoms), demonstrating the 
elongated C-terminal region which prevents the formation of a tetramer. 
 
4.6 The Cofactor and Substrate Binding Sites 
4.6.1 NADPH Cofactor Binding in the Binary Complex 
The cofactor is bound at the C-terminal end of the central β-sheet (strands βB, βA, 
βD and βE) in a binding pocket with a solvent-accessible buried surface of ca. 
1325 Å
2 (Brunger et al., 1998). Strands βC and βF form the two sides of the 
pocket, binding the adenine and nicotinamide moieties, respectively. The cofactor 
is bound in an extended conformation. The degree of extension has been measured 
in other SDRs using the distance between the C6 carbon of the adenine ring, and 
the C2 carbon of the nicotinamide group in a syn conformation (Rossmann et al., 
1975).  In CAD this distance is 13.8 Å, a value similar to other SDRs.  
 
 
 
Figure 4.6 Stereo-figure depicting the binding of NADPH (yellow) in CAD (grey). Water 
molecules are depicted as red spheres, and putative hydrogen bonding interactions as red 
dashes. The 2mFobs – DFcalc electron density map (blue) at NADPH is contoured at 1 δ, 
where δ is the root-mean square electron density for the unit cell. The Helix αFG1 has been 
represented as a loop for clarity. 
 
The NADPH cofactor is composed of three different parts, the adenine moiety, the 
pyrophosphate group and the nicotinamide moiety. The adenine moiety consist of 
an adenine nucleotide connected to a ribose, where the 2’-hydroxyl group is 
substituted for a phosphate group.  The adenine nucleotide is bound in a 
hydrophobic pocket (Gly
14, Ala
38, Val
65, Ala
92, Ile
94), as well as forming a potential 
hydrogen bond to the conserved Asp
64. Arg
39 assists in the closure of cofactor 
binding site, and interacts with the 2’-phosphate group, along with Arg
40. The 
conserved T
13-G
14-X3-G
18-X-G
20 motif is located in the loop between βA and αB.   51 
Ser
16 interacts with the ribose hydroxyl group, while Ser
17 interacts with the 
pyrophosphate moiety of NADPH, hydrogen bonding to one of the phosphate 
oxygens. The other oxygen is coordinated by the carbonyl of Gly
93 via a solvent 
bridge (e.g. water W
73 in the A molecule of the binary complex). The dipole charge 
of helix αB is likely to assist in the stabilization of the pyrophosphate group. Helix 
αFG1 may also stabilize the pyrophosphate group in a similar way, albeit to a 
lesser degree due to its decreased length. The nicotinamide moiety consists of a 
ribose, with a nicotinamide ring bound to it. The nicotinamide ring is bound in a 
pocket consisting of a hydrophobic “floor” (residues Ile
19, Met
140, Pro
185, Thr
188), 
and a polar “ceiling”. The polar residues assist in coordinating substrate binding, as 
well as catalyzing the reduction of the aldehyde. Lys
159 forms bifurcated hydrogen 
bonds to both the 2’ and 3’ hydroxyl groups of the nicotinamide ribose, assisting in 
coordination of the cofactor, as well as lowering the pKa of the catalytic base 
Tyr
155 (Chen et al., 1993) allowing proton transfer as part of the catalytic 
mechanism. 
 
4.6.2 Substrate Binding Site 
Clavaldehyde is an unstable molecule in solution, and thus to circumvent problems 
associated with the preparation and storage of the aldehyde, clavulanic acid was 
used for crystallographic analyses. SDRs often catalyse reversible reactions, and 
this is true of CAD. In this respect clavulanic acid can be also considered a 
substrate of CAD, although the equilibrium of the reaction appears to lie firmly on 
the side of clavulanic acid and NADP
+ (Fulston et al., 2001); Paper II). The 
“soaking in” of clavulanic acid in to a CAD crystal co-crystallized with NADPH 
ensured that a non-productive complex was formed, since clavulanic acid cannot 
be oxidized to clavaldehyde in the presence of NADPH. 
 
Like other SDR enzymes the substrate binding pocket is located in the region 
around helices αFG1 and αFG2. The binding pocket is formed by a small 
invagination of ca. 10 Å, with a surface interaction area of ca. 480 Å
2 (Brunger et 
al., 1998). The binding site is created by the residues in the loops βD–αE (Met
95, 
Leu
97),  βE–αF (Ser
142–Ala
152), and βF–αFG1 (Gly
186, Thr
187). Residues from 
helices αF (Asn
151, Ala
152, Tyr
155, Gln
156) and αFG2 (Thr
201, Tyr
205, Arg
208, Ile
209) 
also contribute to the formation of the binding site, as does the C-terminal Gln
246. 
Although the binding site is located at the periphery of the molecule, a small tunnel 
extends towards the hydrophobic core of the protein, where the catalytic residues 
and cofactor are located. 
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Figure 4.7 Stereo-figure depicting the binding of clavulanic acid (green) and NADPH 
(salmon) in the CAD ternary complex (grey). Water molecules are depicted as red spheres, 
and putative hydrogen bonding interactions as red dashes. The 2mFobs – DFcalc electron 
density map (blue) at clavulanic acid is contoured at 1 σ, where σ is the root-mean square 
electron density for the unit cell.  
 
The binding of clavaldehyde results in the displacement of four water molecules. 
For example, the waters Z
83, Z
110, Z
95, and Z
23 in the binary complex are replaced 
by the C9 alcohol moiety, the O5 oxygen of the C3 carboxyl group, the β-lactam 
ring C4 carbon, and the C7 carbonyl group, of clavulanic acid respectively. Several 
hydrogen bonds secure clavulanic acid within the binding site, such that the C9 
alcohol forms hydrogen bonds to both Ser
142 and the catalytic base, Tyr
155, while 
the C3 carboxyl moiety interacts with Thr
187 and Tyr
205 (Figure 4.7). Additional 
coordination of clavaldehyde is achieved via solvent interactions with Gln
246 and 
Arg
208 (e.g. waters Z
58 and Z
68 in the ternary complex). 
 
 
 
Figure 4.8 The movement of Arg
208 associated with the binding of clavulanic acid. Arg208 
moves from a side pocket in the bindary complex (salmon) to a position directly above 
clavulanic acid (green) in the ternary complex (grey).    53 
Conformational changes associated with substrate binding have been observed in 
other SDRs, e.g. 7α-hydroxysteroid dehydrogenase reductase (Tanaka et al., 
1996). However, in CAD no significant conformational changes were observed 
between the binary and ternary complexes (R.M.S.D = 0.189 Å for the 981 Cα 
atoms of the tetramer). Within the substrate binding site only Arg
208 appears to 
undergo any conformational change upon the binding of clavulanic acid (Figure 
4.7). In the binary complex the Arg
208 side chain lies predominantly to one side, 
leaving a tunnel leading to the substrate binding pocket. In the ternary complex the 
Arg
208 side chain lies directly over the substrate-binding pocket, essentially closing 
the binding site to the external solvent (Figure 4.8). In both the binary and ternary 
complexes the side chain of Arg
208 appears to be quite motile, indicated by the 
higher B-factor (average B-factor = 40.6 Å
2 and 45.4 Å
2, respectively) and poorly 
defined electron density (RSCC = 0.823 and 0.877 respectively). 
 
4.6.3 Reaction Stereochemistry and Mechanism 
The binding of clavulanic acid in the active site positions the C9 carbon is ca. 2.5 
Å above the pro-S hydrogen of the nicotinamide ring. An angle of 123 ° formed 
between the C4 hydrogen of NADPH and carbon C9 of clavulanic acid, consistent 
with the proposed common mechanism for SDR oxidoreductases (Jornvall et al., 
1995; Tanaka et al., 2001) where the 4-pro-S hydrogen of NADPH is transferred to 
the substrates carbonyl group. Clavulanic acid adopts an eclipsed conformation 
within the active site, such that the C9-OH bond projects towards the clavam 
oxygen, being almost coplanar with the O1-C2 and exocyclic alkene bonds (Figure 
4.9a). This is in contrast to the conformation observed in small molecule crystal 
structures of clavulanic acid, where the C9-OH bond points away from the clavam 
ring nucleus (Figure 4.9b) 
 
 
 
Figure 4.9 Clavulanic acid in an eclipsed conformation (A) seen in the binding site of CAD, 
and in an ”open” conformation (B) observed in the small molecule structure (Brown et al., 
1984). 
 
Ornithine is a direct precursor of arginine, such that radiolabelled ornithine is 
incorporated into clavulanic acid. Previous studies using tritium labelled ornithine 
demonstrated that the pro-R, but not the pro-S hydrogen, was incorporated at the 
C9 position of clavulanic acid (Townsend et al., 1986). Furthermore, the 
stereochemistry of the ornithine C5 pro-R hydrogen was inverted, such that it 
occupied the pro-S position (Figure 4.10). The adoption of an eclipsed 
conformation  within the active site is necessary for the hydride transfer to the re-  54
face of the aldehyde. In this way the hydrogen transferred  from NADPH occupies 
the pro-R methylene position of clavulanic acid. 
 
 
 
Figure 4.10 A summary of previous labelling studies showing the incorporation of tritiated 
ornithine clavulanic acid via arginine (Townsend et al., 1986).  
 
The hydrogen bonding of the C9-aldehyde to Ser
142 and Tyr
155 probably promotes 
nucleophilic attack by the hydride. The transfer of the hydride ion results in a 
positive charge on the newly oxidised nicotinamide ring. Such a charge would 
assist the lowering of the pKa of the Tyr
155 hydroxyl group to around pH 6.5–7.0, 
allowing the transfer of a proton from the tyrosine hydroxyl group to the alkoxide 
forming during the reduction step. A mechanism leading to the reprotonation of the 
catalytic Tyr
155 has been proposed for SDRs, where protons are extracted and 
transferred from surrounding water molecules in a small hydrophilic pocket 
(Filling et al., 2002; Oppermann et al., 2003). The proposed proton relay system in 
CAD is shown in figure 4.11b, where the residues Thr
13, Asn
90, Ala
92, Thr
114, and 
Asn
115 may play a role in stabilising the water molecules, facilitating proton 
transfer in an otherwise hydrophobic environment. This is similar to that proposed 
for the 3β/17β-hydroxysteroid dehydrogenase (3β/17β-HSD) (Filling et al., 2002), 
except that the residue corresponding to Ser
114 in 3β/17β-HSD is a glycine residue 
(Gly
118) in CAD. Such a mechanism requires the displacement of the NADP
+ from 
the co-substrate binding pocket, raising the pKa value of the Tyr
155 to allow proton 
extraction. Since large conformational changes are required for the binding of 
NADPH it is also possible that Tyr
155 is reprotonated directly from the solvent. 
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Figure 4.11 CAD catalysed reduction of clavaldehyde. (A) Proposed reaction mechanism. 
(B) Potential proton relay based on the mechanism proposed for the 3β/17β-HSD (Filling et 
al., 2002), where the arrows indicate the path of protons, rather than electrons. Residues 
coordinating waters are shown, as well as distance between water molecules (in Å). ARPP 
is the adenosine ribose pyrophosphate moiety of NADP(H).  
 
4.7.1 Stabilizing the Unstable? 
The clavam bicyclic ring is more strained than the bicyclic ring of the penicillins. 
This is due to the substitution of an oxygen atom for the sulphur atom, the absence 
of a C6 side-chain, and the presence of the exo-β-hydroxyethylidene function at C2 
(Baggaley et al., 1997). The dipole moment of the C9 aldehyde leaves 
clavaldehyde prone to nucleophillic attack, making it an unstable molecule in 
solution; to paraphrase J. Hajdu ” the alkene side chain is like a straw, if you attack 
the C9-aldehyde you suck electrons out of the bicyclic ring, and break it open”. So 
how does CAD catalyse the reduction of such an unstable molecule?  
 
One potential mechanism by which CAD protects the reactive intermediate is in the 
procurement of clavaldehyde away from the aqueous environment of the surface.  
The substrate binding site is located close the surface of the molecule, however the 
reactive C9-aldehyde is buried in the hydrophobic core, thus preventing 
adventitious hydrolysis by water molecules. Another potential mechanism may be 
the shielding of the β-lactam ring. In the binding pocket the β-lactam C7 carbonyl 
is pointing towards a hydrophobic pocket (residues Leu
97, Val
149, Ala
152, Tyr
205), 
and is thus unable to participate in hydrogen bonding. The opening of the β-lactam 
ring by β-lactamases involves the nucleophilic attack of the C7 carbonyl by a 
serine residue. By shielding the C7 carbonyl in the binding site CAD may prevent 
the nucleophilic attack by opportunistic water molecules. Interestingly a similar   56
situation is found in CAS (Zhang et al., 2000), where the monocyclic intermediate, 
proclavaminic acid, is also shielded in a small hydrophobic pocket.  
 
Additional stability during the reduction of clavaldehyde could be achieved by the 
interaction of additional residues during catalysis. Methionines possess a lone 
electron pair, which are capable of hydrogen bonding as well as assisting chemical 
catalysis. Met
95 lies in relatively close proximity to the C9 carbon of clavulanic 
acid, ca. 3.6 Å away, and could easily adopt a favourable conformation allowing 
the lone pair to move closer, ca. 2.7 Å.  Such a mechanism may stabilise 
clavaldehyde during hydride transfer, as well as the alkoxide reaction intermediate.  
 
Another potential mechanism of preventing the degradation of clavaldehyde in 
solution is by limiting the time the aldehyde is exposed to the general solvent of the 
cell. It is possible that a CAD tetramer interacts with directly with the enzyme(s) 
responsible for the synthesis of clavaldehyde to facilitate a rapid transfer of the 
unstable intermediate. At present the gene products of orf10 and orf11 are thought 
to be responsible for catalysing the formation of clavaldehyde, however little is 
known about how this is achieved, nor whether they interact with other enzymes 
(or proteins) from the biosynthesis pathway.   57 
5 ORF15 (Paper III) 
5.1 Background 
Approximately half of the genes in the clavulanic acid gene cluster are open 
reading frames (ORFs), with putative functions assigned based on their sequence 
similarity to proteins of known function (Section 2.3). The role of these ORFs in 
the biosynthesis of clavulanic acid biosynthesis remains unclear (section 2.3.1). 
Orf15 is one of these genes.  
 
Orf15 is thought to be expressed as a polycistronic transcript along with orf16, 
orf17 and orf18 (Mellado et al., 2002). It encodes a 562 amino acid protein, with 
an estimated molecular weight of 61.9 kDa. Sequence comparisons using BLAST 
revealed that ORF15 shares similarity with members of the bacterial periplasmic 
protein-like II superfamily. These bacterial substrate-binding proteins (SBPs) are 
associated with the binding of substrates, which are imported into the bacterial cell 
via the membrane bound permeases of the ATP-binding cassette (ABC) transport 
pathway (Ames, 1986; Higgins, 1992). ORF15 shows the greatest similarity to 
members of the family five SBPs (Tam & Saier, 1993), possessing the 
characteristic sequence motif (PROSITE PS01040), which is represented by 
residues Gly
88 to Tyr
109 (Mellado et al., 2002). ORF15 shows the highest sequence 
similarity with oligopeptide-binding proteins, with ca. 20% sequence identity and 
ca. 40% sequence similarity, including DppA from E. coli and OppA from 
Salmonella typhimurium (Abouhamad et al., 1991; Olson et al., 1991).  
 
ORF15 also shows a 48% amino acid sequence identity with ORF7, which is 
located upstream of Orf15 in the clavulanic acid gene cluster (see Figure 2.1). 
Oligopeptide transporters have not been reported in other antibiotic gene clusters, 
and the apparent requirement for two putative oligopeptide-binding proteins in 
clavulanic acid biosynthesis is rather intriguing. Both orf7 and orf15 appear to play 
an essential role in the production of clavulanic acid (de la Fuente et al., 2002; 
Jensen et al., 2000; Jensen et al., 2004a; Lorenzana et al., 2004) with a complete 
loss of clavulanic acid production associated with the gene-disruption mutants. 
Despite their similarity the two genes show no cross complementation (Jensen et 
al., 2004a; Lorenzana et al., 2004). The gene disruption of orf15 also affected the 
production of 5S-clavams. Jensen et al. (2004a) observed detectable levels of 
alanylclavam in orf15 mutants, while Lorenzana et al. (2004) did not. N-acetyl-
glycyl-clavaminic acid (NAG-clavam) and N-glycyl-clavaminic acid, which have 
only been detected previously in the dcl8 mutant (Elson et al., 1998), were also 
produced by the orf15 mutant, albeit at a much lower levels (Jensen et al., 2004a). 
The non β-lactam antibiotic holomycin was also produced by the orf15 mutants (de 
la Fuente et al., 2002; Lorenzana et al., 2004). 
 
The results of Lorenzana et al. (2004) are consistent with the assigned function for 
both ORF7 and ORF15 as oligopeptide-binding proteins, based on sequence 
similarity. Gene disruption mutants of orf15 mutants were completely inhibited in 
their ability to utilise a nonapeptide (bradykinin) present in the growth medium.    58
This suggests that ORF15 is involved in the uptake of oligopeptide nutrient 
sources, and that both ORF7 and ORF15 possess different substrate preferences. 
Furthermore, mutants of orf7 and orf15 were partially inhibited it their ability to 
transport of the phosphinothricyl-alanyl-alanine (Pt-AA) into the cell. Pt-AA is a 
toxic tripeptide known to enter the cell via the oligopeptide transport system 
(Diddens et al., 1976), and is again consistent with the proposed role of both ORF7 
and ORF15 as oligopeptide-binding proteins. 
 
ORF15 also appears to be involved in additional cellular processes, as mutants of 
orf15 were unable to form aerial mycelium, and thus could not produce spores 
(Lorenzana et al., 2004). This so-called ”bald phenotype” has been observed in the 
Bld gene mutants (section 2.1) which have been well characterised in S. coelicolor 
A3. It is interesting to note that a bald phenotype was not reported for orf15 
disruption mutants in other studies (de la Fuente et al., 2002; Jensen et al., 2004a).  
 
Without a doubt the big question remains: What is the function of ORF15 in 
clavulanic acid biosynthesis?  
 
5.2 Expression, Purification and Crystallization of ORF15 
Orf15 from S. clavuligerus was initially cloned into a pET28a vector, containing 
an N-terminal His6-tag with the sequence MGSSHHHHHHSSGLVPRGS. A 
purification protocol for the his-tagged recombinant protein was developed by 
collaborators in Oxford. It soon became apparent that the purified protein did not 
tolerate freezing at –80 °C, as its ability to crystallize diminished rapidly with each 
successive freeze/thaw cycle. The freezing of the bacterial pellet prior to 
purification also resulted in reduced yields of ORF15, thus the expression and 
purification of the recombinant protein was performed consecutively using a (more 
or less) non-stop protocol described below. 
 
The orf15/His(6) construct was transformed into E. coli BL21 (DE3) cells. Cells 
were grown at 18 ºC in 2YT media containing kanamycin (30 µg ml
-1). Expression 
was induced by the addition of 1 mM IPTG when the culture reached a cell density 
of OD600nm = 0.6–0.8. Initially the temperature was raised to 30 °C, and the cells 
grown for 6 hours. However, for the expression of the Se-Met protein, and 
subsequent native protein, the cells were grown at a constant 18 °C for 18 hours 
after induction. Cells were resuspended in 50 mM phosphate buffer (pH 7.5) and 
lysed by the addition of lysozyme and sonication. The lysate was cleared by 
centrifugation, and the supernatant was loaded onto a Ni-NTA column (GE 
Healthcare). The column was washed with a step-wise gradient of 5% and 10% 
imidazole, before elution of the recombinant protein using a 10%-100% imidazole 
gradient. Samples eluted from the column were frequently collected in small vials 
containing stabilisation buffer, which consisted of 50 mM Tris-HCl (pH 7.5), 5 
mM EDTA and 100 mM NaCl. This was required to prevent partial precipitation 
of the purified protein after elution. The peak fractions were analysed by SDS-
PAGE and pooled before being dialysed overnight in 50 mM Tris-HCl (pH 7.5), 2 
mM EDTA and 100 mM NaCl. Protein was concentrated and subjected to size 
exclusion chromatography (Superdex S200) to yield ORF15 of >90% purity by   59 
SDS-PAGE analysis. The purified ORF15 protein was stored in 5 mM HEPES (pH 
8.0), 1 mM EDTA and 5 mM β-mercaptoethanol. The purified recombinant 
protein corresponded to a band of 64 kDa on SDS-PAGE, consistent with the 
predicted size of the his-tagged protein. Gel filtration suggested that ORF15 was 
present predominantly as a monomer in solution, although aggregates of higher 
molecular weight could be observed eluting in the void volume. 
 
The expression of seleno-methionine protein was performed as above, with the 
following exceptions: the orf15/His(6) construct was transformed into E. coli 834 
(DE3) cells, and grown in SeMet medium™ (Molecular Dimensions Ltd, U.K) 
using L-seleno-methionine, with 5 mM β-mercaptoethanol was included in all the 
purification buffers. 
 
Crystallisation experiments were performed at 18 °C using the sitting-drop vapour 
diffusion method. Crystals were obtained using 20-23% (w/v) PEG6000 in 0.1M 
NaCl and 0.1M Tris/HCl. The crystallization conditions frequently produced a 
mass of small crystals with a morphology resembling a ”sea-urchin”. A seed stock 
was prepared by crushing the sea-urchin crystals, and three-dimensional crystals 
were obtained by seeding of the crystallization drop of the same conditions with 
the seed-stock using a whisker obtained from Felis silvestris sp. Catus. Diffracting 
crystals of Se-Met protein were obtained by seeding into a drop consisting of 1.9 
µL of protein (ca. 9 mg ml
-1) and 1.9 µL of reservoir solution consisting of 14 % 
(w/v) PEG 6000, 0.05 M Tris/HCl (pH 8.0), 0.32 M sodium acetate and 2.5 mM 
MgCl2. 
 
5.3 Structure Determination 
The native crystals varied in diffraction quality, the majority of crystals were 
highly mosaic, with split reflections, and diffracting to only low resolution. 
However, screening of the crystals for improved diffraction identified a crystal 
diffracting to 1.45 Å. A data set was collected at ID14-1 (ESRF, Grenoble, France) 
at cryogenic temperatures. Data were initially processed using 
DENZO/SCALEPACK (Otwinowski & Minor, 1997), where the crystal belonged 
to space group P21, with unit cell dimensions a= 53.6 Å, b= 84.4 Å, c= 62.4 Å, β= 
91.7 °. Attempts to solve the structure using molecular replacement (MR, 
AMORE, PHASER) were unsuccessful . 
 
A single-wavelength anomalous diffraction (SAD) data set was collected on a Se-
Met crystal diffracting to 1.7 Å, at a remote wavelength for selenium (ID14-3, 
ESRF, Grenoble, France). The data were collected using an oscillation angle of 0.5 
° with 720 images collected. The data were initially processed to 1.8Å using 
DENZO/SCALEPACK(Otwinowski & Minor, 1997). The crystal belonged to 
space group P21, with unit cell dimensions a = 53.3 b = 120.8 c = 80.0 β = 94.1 °. 
The inversion of the b and c axes gave an asymmetric unit twice the size of the 
native data. Assuming the presence of two molecules in the asymmetric unit gave a 
VM of 2.1 Å
3 Da
-1 (Matthews, 1968) with 40.1 % solvent. Initially confusion about 
the amount of data collected resulted in the processing of only the first 200 images 
(100 ° rotation). The selenium sites could be located using the SHELX suite   60
(Schneider & Sheldrick, 2002), and the sites refined using AUTO-SHARP (La 
Fortelle & Bricogne, 1997). The NCS between the two molecules could be 
identified in the heavy atom sites using O (Jones et al., 1991), and was apparently 
imperfect preventing electron density averaging. The electron density maps 
produced after solvent flattening in AUTO-SHARP certainly looked like protein, 
however the building a sensible main-chain trace seemed impossible. It appeared 
as if the Se-Met derivative would not deliver the required phasing power. Such 
derivatives are infrequently referred to as ”Kleijwegt” derivatives. 
 
The missing diffraction images were located and all of the data re-processed. 
Solvent flattening and density modification in SOLOMON (Abrahams & Leslie, 
1996), and the use of ARP-wARP (Perrakis et al., 1999) both implemented in 
AUTO-SHARP, resulted in the tracing of an almost complete main-chain trace 
from Arg
7 to Ala
559 in both molecules of the asymmetric unit. No electron density 
could be seen for a small loop (Gly
340-Gly
345) in either of the two molecules. The 
protein sequence could be easily docked by the manual insertion of residues into 
the electron density maps from AUTO-SHARP using O. Attempts to use electron 
density averaging were hampered by an imperfect two-fold non-crystallographic 
symmetry between the two molecules, as a result domain movements. 
 
The data were reprocessed with MOSFLM (CCP4, 1994; Leslie, 1992) and scaled 
with SCALA (CCP4, 1994) to 1.7 Å prior to refinement. The model was initially 
refined in CNS (Brunger et al., 1998) using simulated annealing. Difference maps 
clearly showed the presence of additional density in the binding site of both 
molecules, which was later attributed to the cryo-protectant PEG 400. Refinement 
continued using REFMAC5 (Murshudov et al., 1997), with TLS refinement (Winn 
et al., 2001) used in the final stages with each domain as a TLS group. Solvent 
molecules were added using ARP-wARP (Lamzin et al., 2001) and were manually 
inspected in O. The Se-Met structure was used as a template for molecular 
replacement, however initial attempts were unsuccessful. The re-processing of the 
native data using MOSFLM, and scaling in SCALA, resulted in a structural 
solution. In the native (and substrate complex) electron density for the small loop 
Gly
340-Gly
345 was clearly visible, as was an additional C-terminal residue, Glu
560. 
 
5.4 The Structure of ORF15 
5.4.1 Secondary and Tertiary Structure 
The structure of ORF15 reveals a bi-lobed, pear shaped molecule with approximate 
dimensions of 72 Å x 60 Å x 40 Å (Figure 5.1a). A voluminous cavity is formed in 
between the two lobes (Figure 5.1b), and creates the substrate binding cleft 
(described in section 5.4.2). The protein is composed of 16 α-helices (αA–αP) and 
13  β-strands (β1–β13), which form three β-sheets, arranged in three separate 
domains. The three domains are all members of the α/β-class.  Domains I and II 
form the larger lobe at the ”bottom” of the pear shaped molecule. Domain III forms 
the second lobe, on the ”top” of the molecule. The two lobes are linked by an 
interdomain linker, which permits movements between the two lobes. The structure 
is characterised by a series of meandering loops link the secondary structure 
elements, and account for ca. 60% of the structure.    61 
 
 
 
Figure 5.1 Overall structure of ORF15. (A) The tertiary structure of ORF15 with domains 
indicated with roman numerals and coloured accordingly: domain I (blue), domain II 
(green) and domain III (red), the interdomain linker region is shown in yellow. (B) Surface 
projection of ORF15 showing the large cleft formed between the two lobes. (C) Topology 
diagram showing the arrangement of the secondary structure elements in ORF15, with the 
same domain colouring scheme as in 5.1a. 
 
A topology diagram indicating the arrangement of the secondary structure elements 
is shown in Figure 5.1c Domain I consists of a four stranded mixed β-sheet, and 
four helices, although only helix αA flanks the β-sheet.  The domain is formed by 
three polypeptide segments from separate regions of the sequence (residues 7-64, 
214-297, 533-561), and begins with β1 and αA. After helix αA the chain trace 
departs from  domain I to form domain II (residues 65-213), which is composed of 
two β-hairpins (βB, βB, βC, βD), and four α-helices (αB–αE). The β-strands form 
an antiparallel β-sheet, which is only flanked by one helix, αC. From domain II, 
the chain returns to domain I to form the three additional antiparallel β-strands,   62
(β6–β8), completing the mixed β-sheet. The three additional helices (αF–αH) of 
domain I are also formed, before the chain trace departs domain I to form the first 
of two inter-domain linkers (residues 298–302) linking domains I and III. Domain 
III (residues 303-529) is composed of five β-strands (β9–β13) creating a mixed β-
sheet, which is surrounded by seven α-helices (αI–αP). The β-sheet is flanked by 
helices αJ and αK on one side, and αM, αN and αP on the other, while αK and αL 
lie over the top of the β-sheet. The chain trace departs domain III to form the 
second inter-domain linker region (residues 530–532) before returning to complete 
domain I. 
 
5.4.2 Structural Similarity to Other SBPs 
Previous sequence analysis (Mellado et al., 2002) revealed similarity to bacterial 
SBPs, in particular family five SBPs (Tam & Saier, 1993) which include 
oligopeptide-binding proteins. A search of the structural database using DALI 
(Holm & Sander, 1995) and DEJAVU (Kleywegt & Jones, 1997) confirmed that 
ORF15 is structurally related to the family five SBPs (Table 5.1). These include: 
the dipeptide-binding protein DppA from E. coli (1dpe), and the oligopeptide-
binding proteins, OppA from Salmonella typhimurium (1rkm) and AppA from 
Bacillus subtilis (1xoc), and the nickel binding protein, NikA from E. coli (1zlq). 
ORF15 also showed similarity to several structures obtained in structural genomics 
projects, including a chitin-binding protein from Vibro cholerae (1zty), the 
lipoprotein LpqW from Mycobacterium (2grv), Ylib from E. coli (1uqw), and the 
periplasmic oligopeptide-binding protein (TM1223) from T. Maritima (1vr5). 
While there is structural information for these proteins, a defined function may not 
yet have been demonstrated.  
 
Table 5.1 Sequence and structural similarity between ORF15 and some representative SBPs 
of known structure. A dash line delineates the SBPs possessing three domains, and those 
possessing two domains. 
 
Pdb   S.I 
a S.S 
b R.M.S.D. 
c Lali 
d Lseq2 
e 
1dpe  17.6%  38%  3.9  Å 474 507 
1rkm  18.9%  41.5%  3.9  Å 483 517 
1xoc 17.3% 37.7%  3.9  Å  468  504 
1zlq  17.5%  36.6%  3.2  Å 465 496 
1zty  16.3%  35.2%  4.9  Å 466 528 
2grv  18.9%  34.0%  5.2  Å 452 516 
1lst 10.3%  18.5%  4.5  Å  83  239 
1r9l 12.5%  24.2%  3.5  Å  92  309 
a percentage sequence identity. 
b percentage sequence similarity. 
c positional r.m.s.d of superimposed Cα atoms from the Dali search. 
d total number of equivalence residues. 
e length of the entire chain of the equivalent structure. 
 
ORF15 shares very little structural similarity with the smaller periplasmic SBPs, 
e.g. the lysine/arginine/ornithine-binding protein (LAO) from Salmonella 
typhimurium (llst), and is due to the absence of domain II in these proteins. The   63 
sequence similarity between ORF15 and these proteins is quit low. Some similarity 
can be found between domain III of ORF15 and domain II of the betaine binding 
protein, ProX from E. coli (1r9l). The global comparative statistics can be 
improved by the alignment of individual domains. The arrangement of the three 
domains in ORF15 and the other the family five SBPs is essentially the same, 
although the architecture and folding of the main-chain trace comprising the 
respective domains does differ. 
 
5.4.3 Domain Movements in ORF and Other Related SBPs 
Although many SBPs are co-purified with a ligand this was not the case for the 
recombinant ORF15. However, additional electron density could be seen in the 
cleft for both molecules in the Se-Met structure. This extra density has been 
attributed to the cryo-protectant PEG 400, although the possibility that a PEG 
molecule from the precipitant solution has co-crystallized with ORF15 cannot be 
excluded. The binding of PEG molecules in the cleft gave an initial indication as to 
the location of the substrate-binding site. Furthermore, the native structure revealed 
several glycerol molecules also bound within the binding cleft, in close proximity 
to the arginine binding site (see section 5.4.5). 
 
Solute-binding proteins capture their respective ligands in the cleft formed by the 
two lobes. The binding of ligands by SBPs is associated with domain movements. 
Lobe 1 closes over lobe 2 trapping the ligand in the binding cleft, and thus SBPs 
can be in either an ”open” (unligated) conformation, or a ”closed” (ligated) 
conformation. For example, the dipeptide binding protein (DppA), undergoes a 55 
° rigid body rotation when moving between the open and closed conformations 
(Dunten & Mowbray, 1995; Nickitenko et al., 1995), where as the oligopeptide 
binding protein (OppA) undergoes a 26 ° rigid body rotation (Sleigh et al., 1997; 
Tame et al., 1994). In their closed conformations both DppA and OppA are 
essentially equally ”closed”, and therefore the difference in rotation, i.e. 55° vs 26 
° reflects the relative degree of ”openness” in the crystal structures. Such 
conformational changes have been likened to a Venus fly trap (Quiocho & 
Ledvina, 1996), and firmly ensconce the ligand within the SBP preventing its 
escape. The domain movements associated with substrate binding also offer a 
means by which the ABC transport machinery can recognize the “loaded” protein. 
The rigid-body rotations between the lobes are mediated by changes in the φ and ψ 
angles of residues in the two inter-domain regions linking the two lobes. 
 
A Cα alignment of the ORF15 native (ORF15NAT) structure with the ORF15 Se-
Met ”A molecule” (ORF15MSEA) and ORF15 Se-Met ”B-molecule” (ORF15MSEB) 
revealed a small domain movements up to 14.3° between the structures (Figure 
5.2). ORF15MSEB is most likely to represent the most closed conformation of 
ORF15. While the electron density for several of the side-chains lining the binding 
cleft is marginal, it does appear that further closure of the binding cleft is unlikely. 
Several close van der Waals contacts are formed between the two lobes for 
example Tyr
53 and Ala
428, Tyr
52 and Trp
480, Gln
279 and Lys
401, His
280 and Gly
339, 
Gln
283 and Gln
343. The disorder observed in the small loop of domain III (Gly
340-
Gly
345) is also probably as a result of the loops close proximity to domain I.    64
 
Apart from the relatively small rigid-body domain movements, the side-chain of 
Trp
57 is displaced upon binding of PEG, or arginine (section 5.4.5). As a result of 
this ”Trp flip” the side chain of Gln
189 is also displaced. These two residues remain 
undisturbed in the native structure, despite the presence of glycerol in the binding 
cleft. The binding of PEG also results in a planar rotation of the Tyr
52 side-chain, 
compared to ORF15NAT (and the arginine complex), although this is most likely the 
result of domain movements, rather than directly related to the binding of PEG. 
 
 
 
Figure 5.2 Domain movements between the various molecules of ORF15. (A) Cα alignment 
between the ORF15NAT (black) and ORF15MSEA (grey) structures, where lobe 1 rotates 8.9 ° 
towards lobe 2. (B) Cα alignment of ORF15NAT (black) and ORF15MSEB (grey) where lobe 
1 moves 14.3 ° towards lobe 2.  
 
Given that there is only a ca. 14 ° rotation of lobe 1 onto lobe 2 this would 
suggests that the ”open” conformation of ORF15NAT is already in a predominantly 
closed state. A comparison of ORF15 with other SBPs in their open and closed 
conformations (see Figure 5.3) revealed that ORF15NAT is more closed than DppA, 
and more similar to OppA. On the other hand, the closed conformation of 
ORF15MSEB is more open than the closed conformations of DppA and OppA. 
Interestingly the lipoprotein LpqW from M. tuberculosis appears to have 
crystallized in an already “closed” conformation. A 310 helix in the binding groove 
appears to prevent further closure of the binding cleft, and an inflexible inter-
domain linker region is likely to impair a more open conformation (Marland et al., 
2006). In ORF15 there do not appear to be any factors that would hinder the 
flexibility of a inter-domain region, and it is likely that the relatively closed 
conformation of ORF15NAT is the result of the packing of the molecules in the 
crystal.  
   65 
 
 
Figure 5.3 Structural similarities between ORF15 (black) and other SBPs (grey) in open and 
closed conformations (OC and CC respectively). Statistics refer to the alignment of Cα 
atom for domain III. (A) ORF15 and DppA OC (1DPE, r.m.s.d. = 1.62 Å for 200 atoms). 
(B) ORF15 and DppA CC (1DPP). (C) ORF15 and OppA OC (1RKM, r.m.s.d. = 1.68 Å for 
187 atoms). (D) ORF15 and LpqW CC (2GRV, r.m.s.d. = 1.83 Å for 178 atoms). (E) 
ORF15 and NikA OC (1UIU, r.m.s.d. = 1.78 Å over 181 atoms). (F) ORF15 and ProX CC 
(1R9L).   66
 
5.4.4 Crystal Soaks with Potential Substrates 
Orf15 is likely to be expressed in a polycistronic transcript along with orf16–18 
(Mellado et al., 2002). Orf18 encodes a PBP (PbpA), which possesses a reduced 
binding capacity for β-lactam antibiotics and clavulanic acid (Ishida et al., 2006), 
forming an important part of the self-resistance mechanism. Furthermore, Orf14 is 
located directly downstream of Orf15. Orf14 encodes a putative acetyltransferase, 
sharing sequence similarity with an acetyltransferase from Pseudomonas syringae, 
which is involved in tabtoxin resistance, and may be an important factor in 
conferring antibiotic resistance in S. clavuligerus. In order to see if ORF15 was 
potentially involved in the binding/transport of, or resistance to, clavulanic acid, 
the β-lactamase inhibitor was soaked into crystals at 50 mM for ca. 1 minute.  
 
The production of NAG-clavam, in the gene disruption mutants of orf15 suggests 
that ORF15 is somehow involved in the production of this 5S-clavam. A potential 
substrate analogue of NAG-clavam, N-acetyl-ornithine-glycine, was soaked into 
crystals at 25 mM for ca. 1 minute. 
 
Previous sequence analysis together with the observations of Lorenzana et al., 
(2004) suggests that ORF15 is a potential oligopeptide-binding protein. To test the 
proposed role of ORF15 as an unspecific oligopeptide-binding protein the 
oligopeptides Gly4 and Gly6 were soaked into crystals (20 mM for 5 minutes), as 
were the amino acids phenylalanine, and proline.  
 
The structures of the complexes with potential substrates described above revealed 
no electron density for their respective ligands. Furthermore, no conformational 
changes were observed in the side-chains of Trp
57 or Gln
189, unlike that seen in the 
Se-Met structure.  The cryo-protectant glycerol could clearly be seen in the binding 
cleft, occupying positions similar to those observed in the native structure.  
 
5.4.5 Arginine Binding and the Binding Cleft 
The amino acid arginine, a precursor of clavulanic acid, was soaked into crystals, 
and a data set collected on a crystal diffracting to ca. 1.6 Å. The structure was 
solved by molecular replacement and revealed arginine bound in a negatively 
charged pocket in the cleft between the two lobes. The arginine was bound in close 
proximity to the intersection of the three domains, and did not result in any 
significant domain movements, with an r.m.s.d. of 0.13 Å between the ORF15ARG 
and ORF15NAT structures, consistent with the proposed ”closed” conformation in 
the crystal. This is in contrast to the binding of arginine by LAO (Oh et al., 1994), 
where arginine is firmly encapsulated within the binding cleft by a 52 ° rotation 
between the two domains. Furthermore, LAO forms numerous hydrogen bonds 
with arginine, compared to ORF15 where there are relatively few direct hydrogen 
bonding interactions between arginine and the protein (Figure 5.4a). 
 
The carboxyl oxygen of arginine forms a hydrogen bond to the main-chain nitrogen 
of Gly
454, and a nearby solvent acetate ion, which also forms interacts with the 
hydroxyl oxygen. The positively charged amide nitrogen of arginine interacts with   67 
Asp
456, an interaction frequently seen in oligopeptide binding proteins in order to 
stabilise the amide charge. The charge is further stabilised by the interaction of the 
amide with the main-chain carbonyl of Gly
454 and through the interaction of the π-
electrons from Trp
453. These interactions are mediated through the residues in 
domain III, while the positively charged guanidinium moiety is co-ordinated 
through the residues on lobe 1. The binding of the arginine guanidinium group 
requires the displacement of the Trp
57 side-chain, which in turn displaces the Gln
189 
side-chain. The charge on the NH2 nitrogen is stabilized by the interaction with the 
π-electrons of Trp
57. The NH1 nitrogen is hydrogen bonded to the carbonyl oxygen 
of Ala
455 and Ala
547  via a solvent bridge (W
1 and W
2 respectively). The NH1 
nitrogen forms additional interactions with nearby glycerol (shown in Figure 5.4b), 
which occupies an invagination extending from the binding cleft, towards the core 
of lobe 1, nestled between domains I and II. A second invagination can be found in 
the opposite direction, nestled between domains II and III. The NE nitrogen 
interacts with the main-chain carbonyl of Tyr
52.  
 
 
 
Figure 5.4 The binding of various ligands in cleft of ORF15. (A) The binding of L-arginine. 
The 2mFobs–DFcalc electron density is shown in blue, and is contoured at 1 σ (where σ is the 
root mean square deviation for the electron density for the unit cell). Hydrogen bonding 
interactions are shown as red dashes, and waters as red spheres. The interactions with a near 
by glycerol and acetate molecule are not shown. (B) A superposition of additional ligands 
bound in the ORF15 binding cleft. Part of a PEG 400 molecule (blue) bound in ORF15MSEA 
and three glycerol molecules (green) bound in ORF15NAT. The arginine is shown for 
reference. 
 
The interaction of arginine with tryptophan side-chains is reminiscent of the 
”tryptophan box” found in the glycine betaine-binding protein, ProX from E. coli 
(Schiefner et al., 2004). In ProX, three tryptophan residues are arranged in close 
proximity creating a “Trp box”, such that the π-electrons interact, and stabilize, the 
charge of the ligand. In ORF15 three tryptophan residues (Trp
57, Trp
453, and 
Trp
480) can be found in the binding cleft, although only two appear to participate in 
the binding of arginine. In ORF15 the tryptophan residues are more spatially 
separated, forming less of a “Trp box”, but contributing to a “Trp trap” with which 
to bind arginine.   68
 
In the ORF15NAT structure a glycerol could be identified in two conformations 
bound in close proximity to the position occupied by arginine (Figure 5.4b). A 
glycerol molecule can also be found at an additional position in the binding cleft, 
away from the arginine binding site, in a positively charged area of the binding 
cleft.  
 
5.5 The Function of ORF15 
At the beginning of this chapter I posed a question. Now that we know the structure 
of ORF15, do we know its function? Unfortunately the answer is no, but the 
structure does give some important information, and clues as to a potential 
function. 
 
In trying to understand the function of ORF15 we first need to consider its location 
in the cell. In Gram-negative bacteria SBPs are secreted into the periplasm space, 
which is located in between the inner and outer membranes. Potential substrates, 
such as oligopeptides, enter the periplasm through porin proteins in the outer 
membrane, and are subsequently bound by the SBPs. The binding of the substrate 
by the SBP results in a conformational change between the two lobes, which assists 
the ABC transporters (permeases) recognise the loaded SBPs. The permease then 
actively imports the substrate into the cell, where ATP is hydrolysed in the process. 
In Gram-positive bacteria, SBPs must first cross the cell wall, before being tethered 
to the cell wall in close proximity to the integral components of the transport 
system. In both cases the protein requires an N-terminal signal peptide indicating 
that is should be secreted outside the cell. In the case of Gram-positive bacteria the 
SBP also requires a means by which it can be attached to the outer membrane, 
either by a trans-membrane N-terminal helix, or by a lipid attachment site 
(PROSITE PDOC00013). In the latter the secretion signal peptide is cleaved, and 
the protein is covalently attached to a lipid molecule via a cysteine residue. 
 
Sequence analysis reveals that ORF15 lacks an N-terminal signal peptide for 
secretion via the Sec pathway (Bendtsen et al., 2004). Furthermore, ORF15 lacks 
an N-terminal trans-membrane helix, lipid attachment motif, or sufficiently large 
hydrophobic patch with which the protein could interact with the lipids of the outer 
cell wall. Folded proteins can be secreted from the cell via the twin arginine 
translocase (Tat) pathway (Berks et al., 2003), which possesses an N-terminal 
signal peptide with a RRxΦΦ motif, where Φ denotes a hydrophobic residue. 
While ORF15 does possess several twin arginines, in particular  R
6R
7 and 
R
29R
30R
31 in the N-terminal, it does not appear to possess the entire signal peptide 
(Bendtsen et al., 2005). Taken together the sequence data suggests that ORF15 is 
localized in the cytoplasm. However SBPs are not localized within the cytoplasm, 
they are found either attached to the cell wall or in the periplasmic space. Recent 
observations using cryo-electron microscopy (Matias & Beveridge, 2005; Matias 
& Beveridge, 2006) suggest that, at least some, Gram-positive bacteria possess a 
small “periplasmic space” associated with the cell wall. Although this remains to 
be determined for S. clavuligerus, should such a periplasm exist, then it may be 
possible that ORF15 is located in this space. This would negate the need for a   69 
means by which it attaches to the intracellular cell wall, although how ORF15 
would be transported across the cytoplasmic membrane remains unclear. Since the 
cellular location of ORF15 requires further investigation, the potential role of 
ORF15 in either the cytoplasm or potential periplasm/ or cell wall will be 
discussed. 
 
5.5.1 Is ORF15 a Potential Cytoplasmic “Intermediate Chaperone”? 
The binding of arginine by ORF15 is of great interest since arginine is a precursor 
of clavulanic acid. The presence of three ornithine acetyl transferases, Oat2 in the 
clavulanic acid gene cluster (Kershaw et al., 2002), Oat1 in a paralogous gene 
cluster (Tahlan et al., 2004b) and ArgJ elsewhere in the genome (de la Fuente et 
al., 2004), suggests that the accumulation of arginine is important in S. 
clavuligerus. It is therefore possible that ORF15 is involved in the procurement, 
and possible transport, of arginine within the cytoplasm for is subsequent 
conversion into clavulanic acid and 5S-clavams. Glycerol, which was found in 
several locations in the binding cleft, bears some resemblance to the other 
clavulanic acid precursor, D-glyceraldehyde-3-phosphate (G3P). There does not 
appear to be any volume constraints preventing the binding of G3P, however 
residues capable of coordinating the negatively charged phosphate group appear to 
be lacking, at least in the arginine binding site. It is interesting to note that on either 
side of the negatively charged arginine binding site, there are positively charged 
surfaces, where a cryo-protectant molecule can be found bound, although this 
glycerol appears to only be partially bound, as demonstrated by elevated B-factors. 
 
Extending this potential role, ORF15 may act as an ”intermediate chaperone” 
assisting the production of clavulanic acid, by preserving the pool of intermediates. 
Many of the intermediates in clavulanic acid are unstable molecules in solution, in 
part due to the β-lactam ring. Since arginine does not occupy the entire binding 
cleft, there may be additional space for the “side-chains” of the first intermediate of 
the biosynthesis pathway, e.g. N
2-(2-carboxyethyl)-arginine, and 
deoxyguanidinoproclavaminic acid. In the process of binding of arginine (or PEG) 
the side chain of Trp
57 is flipped to an alternate conformation to make sufficient 
space for the guanidinium group, as well as stabilise one of the positively charged 
nitrogens. It is therefore possible that other side-chains within the binding cleft 
may permit the binding of other clavam intermediates, for example NAG-clavam. 
The potential binding of NAG-clavam requires further investigation, as N-acetyl-
ornithine-glycine may be an unsuitable substrate analogue.  
 
It is difficult to reconcile the differences between a complete loss of clavulanic 
acid production observed in orf15 mutants, and the proposed role of ORF15 as an 
intermediate chaperone. Indeed, if ORF15 were to act as a chaperone, then a 
reduction in clavulanic acid might be expected, due to a reduction in the pool of 
clavam intermediates. Detectable levels of 5S-clavams have been observed in 
mutants of orf15 mutant, albeit at reduced levels (Jensen et al., 2004a), although 
Lorenzana  et al., (2004) were unable to detect 5S-alanylclavam. While the 
production of 5S-clavams is often more varied, if ORF15 acted as a intermediate 
chaperone a reduction in 5S-clavams would be expected, since both 5S-clavams   70
and clavulanic acid share a common biosynthesis pathway, at least until clavaminic 
acid (Egan et al., 1997). 
 
5.5.2 Is ORF15 a Potential Periplasmic Oligopeptide Binding Protein? 
The increased resistance to the toxic tripeptide Pt-AA and the inability to utilize a 
nonapeptide (bradykinin) in the growth medium in mutants of orf15 (Lorenzana et 
al., 2004) appears consistent with the proposed role for ORF15 as an oligopeptide-
binding protein. The structure of ORF15 is also consistent with this proposed role, 
sharing structural similarity with other oligopeptide binding proteins.  
 
The size of the peptide substrate bound by oligopeptide-binding proteins, e.g. 
dipeptide  versus pentapeptide, is dependent on the size of the binding pocket, 
rather than the sequence of the substrate peptide. Polar side-chains lining the 
substrate-binding pocket coordinate the hydrogen bonding of the peptide’s main-
chain atoms. The positive charge of the peptide’s N-terminal amide is frequently 
stabilized by the interaction with an aspartic acid residue, while the C-terminal 
carboxyl residue is often found interacting with a charged glutamic acid side-chain. 
Water molecules move in and out of the binding pocket depending on the size, and 
hydrophobicity, of the peptide’s side-chains. The peptides polar side-chains are 
coordinated via solvent bridges to polar residues lining the binding pocket which 
occupy the substrate-binding cleft. 
 
ORF15 possesses a large binding cleft, potentially capable of binding 
oligopeptides of several residues. Several aspartic acid residues, can be found 
within the binding cleft, and other polar residues capable of coordinating peptide 
main-chain residues are present. The observed binding of arginine within the cleft 
may explain the apparent import of bradykinin, since the nonapeptide possesses 
both an N- and C-terminal arginine in its sequence (RPPGFSPFR). The binding of 
bradykinin is most likely non-specific, since the oligopeptide-binding protein 
AppA has also been observed to bind longer peptides, including bradykinin (Picon 
& van Wely, 2001). The attempts to bind the oligopeptides Gly4 and Gly6 in 
ORF15 crystals were unsuccessful, but this does not necessarily exclude a role for 
ORF15 as an oligopeptide-binding protein. Indeed, the relatively closed 
conformation of ORF15 in the crystals may restrict the binding of small 
oligopeptides, but favour the binding of amino acids, although ORF15 does not 
appear to be a non-specific amino acid binding protein. Furthermore, no ligands 
were co-purified with ORF15, suggesting that there is some specificity in substrate 
preference. 
 
Periplasmic and extracellular SBPs associated with the ABC transport system are 
responsible for the import of nutrients into the bacterial cell; they also participate 
in additional cellular processes, including the initiation of chemotaxis, and the 
binding of signalling molecules stimulating morphological development (Koide & 
Hoch, 1994; Lazazzera & Grossman, 1998; Solomon et al., 1996). For example, a 
number of genes have been identified in a signalling cascade ultimately leading to 
the formation of aerial mycelia in S. coelicolor A3 (Nodwell et al., 1999). Mutants 
of the Bld genes are unable to develop aerial mycelia, and thus possess a bald   71 
phenotype. The BldK operon in S. coelicolor A3 encodes five genes (A–E) with 
homology to the ABC transporters (Nodwell et al., 1996). One of these genes, 
BldKB encodes a putative oligopeptide-binding protein involved in signal 
reception and/or transport. BldKB apparently binds a 665 oligopeptide, containing 
serine and glycine residues (Nodwell & Losick, 1998), which in turn stimulates a 
signalling cascade, ultimately leading to the formation of aerial mycelia. 
 
The reported “bald” phenotype associated with the orf15 mutant (Lorenzana et al., 
2004) implies that ORF15 may also be involved in similar processes. Both ORF15 
and BldKB share ca. 44% sequence similarity, although BldKB possesses both a 
N-terminal signal peptide and lipid attachment motif (PROSITE PDOC00013) 
associated with extracellular oligopeptide-binding proteins. Furthermore, BldKB 
possesses a potential ATP/GTP “P-loop” (PROSITE PS00017), which provides a 
potential means for propagating a signal upon binding of the signalling peptide. 
While ORF15 lacks such a nucleotide-binding site, it may still be involved in 
potential signalling pathways. For example, the small changes observed between 
the open and closed conformations in ORF15 might be significantly larger in 
solution, and thus permit interaction in signalling pathways via Venus fly trap 
movements, like other SBPs. Peptides accumulating in culture broths have been 
shown to stimulating antibiotic production in fresh medium cultures (Sanchez & 
Brana, 1996). Thus it may well be that morphological development and β-lactam 
antibiotic/ clavulanic acid production is stimulated by oligopeptide signalling 
molecules. This then raises further question: why are there two apparent 
oligopeptide-binding proteins in the clavulanic acid gene cluster?  
 
5.5.3 Structural Similarity Between ORF15 and ORF7? 
Proteins with a similar sequence often possess a similar structure, where higher 
sequence similarity/identity implies higher the structural similarity. Such rational 
allows for the predicted three-dimensional modelling of a protein structure based 
on its sequence similarity to known structures. The reliability of such methods are 
of course dependent on the amount of information available and the degree of 
sequence similarity identity, with the axiom being ”the higher the better”. ORF7 
and ORF15 share 48% sequence identity, and 63% sequence similarity.  Does the 
structure of ORF15 tell us anything about the structure of ORF7? Perhaps this is a 
rhetorical question, since we have not yet predicted a model for ORF7 based on the 
structure of ORF15. 
 
ORF7 is most likely a bi-lobed, pear shaped molecule, composed of three domains.  
Two of the tryptophan residues located in the ORF15 binding cleft are conserved 
in ORF7 (Trp
57, Trp
453), as is the aspartic acid binds the arginine amide nitrogen 
(Asp
456). The third tryptophan is replaced by a glutamine, providing a residue with 
hydrogen bonding potential. A data set has been collected on an ORF7 crystal, and 
attempts to solve the structure using ORF15 as a molecular replacement template 
have so far been unsuccessful (K. Valegård, S. Lejon, Per. Comm.). This is most 
likely due to ORF7 being in an alternate conformation with respect to the two 
lobes, although other factors may complicate the molecular replacement procedure. 
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1 MTTAARRPAPTTAGAGWDAGVGALVNPSRRRGGTLRLVSSADVDSLDPARTYYVWVWLLQ 60 
2 ----METTRSTTADEGFDAGVRGVVAPTDAPGGTLRLVRTDDFDSLDPGNTYYAYTWNFL 
                                                      * 
1 RLLNRTLMAYPTDPGPAGLVPAPDLAEGPGEVSDGGRTWTYRLRRGLRYDDGTPITSDDV 120 
2 RLIGRTLVTFDTAPGKAGQRLVPDLAESLGESSEDGRVWTYRLREGLRYEDGTPVVSADI 
 
1 RHAVQR-VFAQDVLPGGPTYLIPLLDDPERPYPGPYRTDEPLRSVLTPDEHTIVFRLTRP 180 
2 KHAIARSNYGTDVLGAGPTYFRHLLG-TEYGGPWREPDADGPVTLETPDERTLVFRLREP 
 
1 FSDFDHLMAQPCAAPVPRRSDTGADYGRDPRSSGPYRVARHEPDTLLHLERNPHWDRATD 240 
2 FAGMDLLATMPSTTPVPRDRDTGAEYRLRPVATGPYRIVSYTRGELAVLEPNPHWDPETD 
 
1 PIRPALPDRVELTIGLDVDVLDARLIAGEFDINLEGRGLQHAAQRRATADEVLRSHTDNP 300 
2 PVRVQRASRIEVHLGKDPHEVDRMLLAGEAHVDLAGFGVQPAAQERILAEPELRAHADNP 
 
1 RTSFLHFVAMQPHIPPFDNVHVRRAVQYAADKILLQDARGGPVNGGDLTTALFPPTLPAH 360 
2 LTGFTWIYCLSSRIAPFDNVHCRRAVQFATDKAAMQEAYGG-AVGGDIATTLLPPTLDGY 
 
1 QDLDLYPTGPDLRGDLDAARAELAAAGLPDGFRAVIGTQ--RGKFRLVADAVVESLARVG 418 
2 KHFDRYPVGPEGTGDLEAARAELKLAGMPDGFRTRIAARKDRLKEYRAAEALAAGLARVG 
 
1 IELTVKELDVATYFSLGAGHPETVREHGLGLLVTDWGADFPTEYGFLAPLVDGRQIKRNG 478 
2 IEAEVLDFPSGDYFDRYGGCPEYLREHGIGIIMFGWGADFPDGYGFLQQITDGRAIKERG 
                                   * 
1 GNWNLPELDDPEVNALIDETLHTTDPAARAELWRAVERRVMEHAVLLPLVHDKTLHFRNP 538 
2 -NQNMGELDDPEINALLDEGAQCADPARRAEIWHRIDQLTMDHAVIVPYLYPRSLLYRHP 
    * 
1 WVTNVYVHPAFGLYDIQAMGLAEED 
2 DTRNAFVTGSFGMYDYVALGAK--- 
 
Figure 5.5 The sequence similarity between ORF15 (1) and ORF7 (2), where identical 
residues are highlighted in grey. A (*) indicates the position of the three tryptophan residues 
in the ORF15 binding cleft. 
 
No additional ligands were co-purified with ORF15, which suggests that there is 
some relative specificity in substrate preference. The opposite appears to be true 
for ORF7, which is purified with additional, as yet unidentified ligands (S. Lejon, 
Per. Comm.). This suggests that ORF15 is a substrate specific oligopeptide-binding 
protein, while ORF7 is more unspecific. Furthermore, while ORF15 contains twin 
arginines in its N-terminal sequence, ORF7 does not. Is it possibly that ORF7 is 
localised in the cytoplasm, and that ORF15 is transported across the cell via the 
Tat pathway? 
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6. Future Prospectives 
6.1 DAOCS 
The initial task of altering the packing of protein molecules in the crystal using a 
His(6) tag was successful. The crystals of the His-tagged protein showed a different 
crystal packing, resulting in a non-twinned crystal. Unfortunately, the increased 
solvent content of the crystals probably contributed to a significant reduction in the 
diffraction of the crystals. The new crystals did not diffract at sufficient resolution 
to detect the small differences caused during ferryl formation. The addition of 
different purification tags in order to disrupt the packing of the protein molecules 
in the crystal is still an interesting option. Using the techniques developed in high 
through-put crystallography it would be possible to screen a large number of 
different constructs simultaneously. Perhaps the hardest decision boils down to the 
choice of which purification tag to add. Both the His-tagged DAOCS, and Trx-His-
tagged CAD provide a nice example of how purification tags can affect the 
crystallization (or lack there of) of a protein. 
 
The challenge of trying to capture the ferryl intermediate still remains for any soul 
brave enough to accept. It may still be possible to use the twinned R3 crystals using 
the philosophy that sheer force by numbers will eventually identify crystals with a 
sufficiently low twin fraction. Given the recent advances in automation for both 
crystallization experimental set up and screening of crystals at synchrotrons, it 
should not be too long before an armchair crystallographer can sit at home, and 
click their way through a thousand crystals grown essentially a robot.  Of course 
this is little conciliation to the biochemist who still has to purify DAOCS using the 
extended protocol, or the joy of preparing crystals under anaerobic conditions. 
 
6.2 CAD 
Now that we have the structure of CAD can we expect an intensive project of 
protein engineering to improve the enzymes performance? From an industrial point 
of view this is unlikely to occur in the near future. However, in the long term it is 
possible to envisage engineering of the CAD binding site. If the mechanism by 
which the 3S,5S-clavams undergo enantiomerisation can be identified, and the 
process industrialised, then a plethora of new potential β-lactamase inhibitors 
could be made. By the modification of the CAD binding site, new potential 
substrates could be accommodated and reduced to more stable alcohols. 
 
From a purely academic point of view the structure of CAD is interesting. The 
observed binding of clavulanic acid in an eclipsed conformation within the binding 
site was unexpected, and rationalises previous labelling experiments. Furthermore, 
the potential mechanisms by which CAD protects the labile substrate are of great 
interest, given the instability of many of the clavam intermediates.    74
 
6.3 ORF15 
Where to even begin? The structure has revealed some tantalizing hints as to the 
function of ORF15, but no clear role in clavulanic acid biosynthesis has yet 
emerged. The two proposed roles require further investigation using a combination 
of different techniques. The location of both ORF7 and ORF15 in the cell will be 
important in determining the function of the proteins. The observed ”Trp flip” seen 
in the binding of arginine or PEG can be used to screen the binding of potential 
substrates using tryptophan fluorescence. Although the signal may be diluted by 
the other eight tryptophans, potential intermediates could be added to the protein in 
solution, and their binding monitored via the changes in fluorescence. Furthermore, 
our Oxford collaborators have expressed and purified CEAS, BLS, PAH and CAS 
and mixed them in vitro with glyceraldehyde-3-phosphate and arginine in an 
attempt to produce clavaminic acid, with reasonable success. It would be 
interesting to add ORF15 to the enzyme cocktail and see if the clavaminic acid 
production was improved Alternatively, ORF15 could be immobilize on an Ni-
NAT column and fractions isolated from lysed S. clavuligerus cells wash through 
the column. The protein could be eluted and ligand binding monitored using Mass-
spectrometry. 
 
Comparing the structure of ORF15 with ORF7 is an exciting prospect. How similar 
are the structures? From outward appearances ORF7 looks to be an unspecific 
peptide-binding protein.  How do the binding sites differ? Why is ORF7 less 
selective than ORF15? Where are the ORFs located in the cell? Why are there no 
apparent ABC permease genes in the clavulanic acid gene cluster? So many 
questions remain. 
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Adam, for that strange party in Oxford, and even stranger pub afterwards. S. Iwata, 
for great office organisation skills, and for being so focused at the beamlines. 
Hanna and Abe for aweful jokes, entertaining puns and for your amazing energy 
and lust for life- you guys are an inspiration 
 
Thanks to Gisela, for all the dinners/parties and for general energy. For a fun time 
in Tassie land, and for being so positive and entertaining. 
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expeditions, and for headless chicken complaints at boulder open. For all those 
parties and late night snusing of Cuban cigars. 
 
Thanks to Talal for being the social butterfly. For your passion for life, all those 
dinners, parties and discussions on anything and everything. For your cheeky antics 
and sense of humour. For slaying me in squash, for climbing and being a fashion 
critic (at the same time). 
 
A big thanks to my old office mate Anke, for your fantastic laugh, and for 
interesting dutch expressions, for teaching me crystallography, explaining how 
things work, and being amazingly patient. For skating trips, and late night talisman 
sessions, for being so enthusiastic, and a wonderful person. 
 
A big thank you to the SLU crowd: 
Kenth for a wicked session of late night quake and beer, and general fun and 
entertainment. Deva and Rams for giving me so much grief about cricket, and for 
being so damn entertaining. Andreas K (and Miss G) for the days of liver damage, 
music, no sleep and hamburgers, music, music, and watching crazy Finns. Thanks 
for the Britney fan mail too. M. Forstner for interesting climbing atire, and for 
“umpa umpa” beer music to a techno beat in an audi at 120 kmph on E4. Fredrik, 
for climbing adventures (plastic, rock, ice), dinners/parties and the “cheese and 
scotch” incident. Thanks for being so passionate about science. Andrea for being 
such a cool Grrrl, for letting me try the cello, the parties, music, ski trips to 
Romme, and for humouring Fredrik by pretending to be interested in Dicty. Lotta 
for always being up for something fun, for coming to the synchrotron and for 
looking after beer club. Professor Urszula for the parties, for falling asleep on the 
couch at BM14, for all the fun on the ESRF trips, and for introducing me to the 
obsession with small pickles. Rosie and Malin, for karaoke at Tällberg, for 
outstanding entertainment late at night at the ESRF, for the ski trip, and some 
inspirational rally driving in the mountains of France. How many guys on a rugby 
team? Magareta for advice on seeding and crystallization. Nisse for entertainment 
on synchrotron trips. Christer for fixing the TV, for mean go-kart tactics, and for 
wearing a tie. Martin for getting us organised with group meetings, for previous 
president duties, and for entertainment late at night on the beamlines. Stefan for 
being such a cool professor, for late night discussions on science and world travel, 
and for keeping the department running. Wimal for being such a nice guy, for 
making sure everyone is OK, for late night chats at Tällberg. Sanjeewani for 
keeping me company on Sherry’s course. Saeid for entertainment at the ESRF, and 
for always saying “I’m too old for this” and then staying up later than the 
youngsters anyway. Ellenor for keeping my paper work under control and things 
running smoothly around the department. Ulla for entertainment at the ESRF, for 
departmental organisation, and making sure everyone is happy. Jonas for the way 
in which your scary minds works, for being obsessed with bizare internet things, 
and for all those crazy stories. Agata for being a beer queen, and such a social 
person, for keeping me company in Sherry’s course. Anton for being working 
interesting hours, and for being such a smart guy, for interesting stories, and for 
always listening to any protein problems. Sherry for running a great protein course.   89 
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meetings, and for asking questions. Hasse for being so relaxed, for your advice and 
comments. Welcome to the group Rie. Jerry for music, dancing, and being a party 
animal. Mats for coffee room entertainment. 
 
Thanks to my first collaborators out at SLU, Monika and Carina. Thanks for all the 
help with NDPK, sorry we didn’t get that S69 mutant to work. 
 
Thanks to my second collaborators in Oxford. Chris for all those helpful 
comments, and for looking after us all in Oxford. Nadia for help with CAD, for 
taking really good care of me in Oxford, and for all your useful comments and 
advice. Matts and Mark for looking after us. 
 
To the wonderful computer nerds that make the 0’s and 1’s go around. Erling, 
David, and Remco - you are the heads of department, it is chaos without you. 
 
Thanks to the upstairs people: 
To the Åqvist lads (Johan, FredrikViktor, Jens, Martin, Martin and Martin, Lars 
and Stefan) for ultimate frisbee and general entertainment in the coffee room. 
Sinisa for help with enantiomer docking, and for finding outrageous bouldering 
problems. Jimmy for being probably the best beer club co-president in the world, 
for your driving skills in a go-kart or out on the open road at 1 am with no lights 
and determination. For saving me from the water at Karls mid-summer party. 
Seved for Tipset, Daniel for being just a little bit crazy- in a good way, and for 
being such a gadget nerd. Patrik for never saying no to any form of adventure. For 
all the skating, skiing, climbing trips, added value on synchrotron trips, discussion 
on photography, and for trying to teach me obscure norrland phrases. Torsten for 
all the singing, chuckles and generally festive atmosphere. Alina for Grrrrl power, 
energy, and for being crazy in a good way. Lena for lunchroom entertainment, and 
for getting people organised when it comes to singing, or party like activities. 
Annette and Nisse- for all the parties/BBQs, late night beer clubs, climbing trips 
(plastic and rock). For always being up for an adventure in any form, and for being 
so damn entertaining. Tex for being so damned organised, and for teaching me a 
trick or two about crystals. Christofer for the obsession with food, and for 
interesting theories on what should be done with GM virus’. Eva Lena for black, 
and popping around late at night to entertain at synchrotrons. Wojciech, Pavel, 
Magnus for interesting luch time conversations. Nina, for trying to teach me 
Swedish all those years ago, and for great cloning advice. Henke for being a 
walking wikipedia, for all the stories and ice tips, and for driving me off the track 
at the Go-kart race. Smiley Anna for being such so much fun. Cuba Anna for 
climbing (rock and ice) oh so long ago, for parties and slam dancing- where’s me 
jumper, and late night discussions about Cuba. Adrian for being such a friendly 
guy, and wicked dancer. Gerard (aka DVD) for all the red dwarf, and for helping 
me rediscover my inner punk rocker, for the interesting music, for answering about 
10,000 stupid crystallography questions, and for the nerdy stuff like USF and EDS. 
Lars for trying to teach me crystallography, and for lunch time discussions. Alwyn 
for singing in the corridor, amusing stories, terrorising people and for trying to 
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general entertainment at coffee breaks. Fariborz for being such excellent value, for 
the belays at the climbing wall, and for all those discussions. Emma, for trying to 
teach me Swedish so long ago, for all those dinners and parties, for nude drawing, 
discussions about music, telemark adventures, and iceskating, for always looking 
on the positive side, and for your energy and determination. Bror for being a 
legend. 
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Martin, for always being so willing to help, for Wednesday nights at Fellini’s and 
METAL! For being the most evil quake player ever, and for help with the 
molecular biology. Karin, huge thanks for ORF15 and all the support that has come 
with it. For being such a data collection wizard, and for keeping us under control 
while in France. Sara, for your passion for life, for all those late night laughs on the 
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person. Tom for being such a braniac when it comes to CNS, averaging, and 
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photography nerd, for lunch time chats, and assistance with docking. Alexandra for 
being such an enthusiast, for all your energy, and chats on skype. Filipe for 
ultimate frisbee, and always up for fun. Nicusor for vampires, lard, politics, 
quantum physics, and all the other nonsense we talk about, for your insightful 
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To all the people outside of work who have made the years in Uppsala very 
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always being so friendly and sharing the obsession. Shawn, Kristin and Damian for 
all your energy, adventures and for being truely wonderful people, and for 
discussing socialism for 3 hours in a sauna (Shawn). Tina, Emil and Linus for not 
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for being a fashion queen, party animal, and always being willing to try something 
else. Mathias (and family) for looking after us in Grenoble, and pointing us to the 
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for the Oxford pints. Pia and Per, and miss V for looking after us in Göteborg. 
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miss those waves and brews. Alex for looking after us in London, and for your 
passion for life. The 346 sandy bay crew: Kate, Jenny, Chris, Jimmy and 
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To my parents Ken and Alison, for their love and support over the years- miss you 
guys. To my brother Bogle, mad man and maniac for all sorts of mischief, miss the 
adventures. To Kajsa and Bullen, my other parents, thanks for taking such good 
care of me. Oskar, Kajsa and little Saga, Kalle and Poie and Pucko-Nico- thanks 
for all the fun and entertainment you guys bring with you. 
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baby! 
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